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Abstract	Introduction:	Sudden	cardiac	death	(SCD)	in	young	people	(ages	2-40)	is	a	tragedy	for	families	and	communities	alike.	It	has	multiple	causes,	one	of	which	is	an	underlying	genetic	arrhythmogenic	cardiomyopathy.	A	study	from	Ontario	(ON)	using	a	2008	cohort	assessed	the	incidence	of	SCD	in	persons	aged	2-40	years	to	be	2.64/100,000	person-years.	We	hypothesized	that	Newfoundland	&	Labrador	(NL)	may	have	a	higher	incidence	of	early	SCD	in	ages	2-40	due	to	possible	underlying	genetic	causes	given	the	historical	genetic	isolation	of	the	population	and	the	founder	mutations	already	identified	(ex.	PKP2,	RYR2,	TMEM43).		Methods:	We	ascertained	cases	of	sudden	death	from	the	comprehensive	Medical	Examiners’	provincial	database	for	the	years	2008	and	1997;	2008	as	a	direct	comparison	to	ON,	and	1997	as	it	represented	a	time	when	the	implantable	cardioverter-defibrillator	was	not	available	in	NL.	Each	case	of	sudden	death	was	individually	analyzed	to	determine	likelihood	of	SCD.		Results:	There	were	119	cases	in	2008	and	157	cases	in	1997.	The	incidence	of	SCD	for	ages	2-40	in	2008	was	7.32/100,000	persons.	This	was	significantly	higher	than	the	incidence	in	Ontario.	The	incidence	of	SCD	was	not	significantly	higher	in	1997	than	2008.	Coronary	artery	disease	was	a	major	cause	of	death	in	all	cohorts,	similar	to	Ontario	(non-significant	difference).	Conclusion:	In	general,	there	was	a	trend	of	more	arrhythmogenic	deaths	in	the	young	and	more	structural	cardiac	deaths	as	age	increased.	This	reflects	the	cause	of	SCD	in	the	young	is	often	genetic	in	nature,	while	older	deaths	are	often	due	to	
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coronary	artery	disease,	a	disease	heavily	influenced	by	environment.	To	conclude,	SCD	in	NL	occurs	at	a	higher	incidence	than	ON,	further	research	is	needed	on	the	topic.		
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Sudden	death	is	a	devastating	event	for	families	and	communities	alike.	Worldwide,	the	estimated	burden	of	sudden	cardiac	death	(SCD)	is	4-5	million	cases	per	year	(Chugh	et	al.,	2008).	Sudden	unexpected	death	(SUD)	is	defined	as	the	sudden	death	of	an	individual	who	appears	healthy	and	dies	suddenly	within	a	few	minutes	to	several	hours	due	to	pre-existing	disease	or	functional	disorder.	SUD	is	further	defined	by	the	anatomical	cause	of	death	after	investigation	i.e.	which	system	is	responsible	for	the	death:	is	it	the	cardiovascular	system,	the	respiratory	system,	the	central	nervous	system	etc.	The	cardiovascular	system	is	implicated	when	an	autopsy	finds	evidence	of	cardiac	injury,	thus	SUD	becomes	SCD.	The	cardiovascular	system	is	also	implicated	when	absolutely	no	anatomical	cause	is	found	on	autopsy,	as	then	a	cardiac	arrhythmia	was	assumed	to	have	occurred.	In	the	latter,	diagnosing	SCD	is	much	more	difficult	as	all	other	causes	of	death	must	be	excluded	–	which	is	to	say	all	means	of	investigation	must	be	exhausted	Overall,	SCD	is	a	difficult	diagnosis	to	make,	as	it	is	easy	to	miss	given	there	may	not	be	any	physical	findings	on	autopsy	of	arrhythmias.		
SCD	is	typically	observed	in	the	older	population;	however,	a	portion	of	cases	do	occur	in	the	young,	without	any	prior	symptoms	(Kauferstein,	Kiehne,	Neumann,	Pitschner,	&	Bratzke,	2009).	In	the	older	population	the	cause	of	SCD	is	often	related	to	coronary	artery	disease	(CAD).	CAD	is	heart	disease	caused	by	a	buildup	of	plaque	in	the	coronary	arteries	that	may	eventually	lead	to	blockages.	When	dealing	with	the	young,	many	other	etiologies	are	present,	including	structural,	metabolic,	and	
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genetic	mutations	that	increase	arrhythmogenic	predisposition	(Noseworthy	&	Newton-Cheh,	2008).		
Newfoundland	&	Labrador	(NL)	is	a	founder	population,	with	a	high	incidence	of	some	genetic	diseases	(Rahman	et	al.,	2003).	This	is	the	result	of	the	founder	effect:		a	loss	of	genetic	variation	that	occurs	when	a	new	population	is	established	by	a	very	small	number	of	individuals	from	a	larger	population.	It	has	been	estimated	that	90%	of	the	current	NL	population	has	arisen	from	20,000	to	30,000	original	European	settlers	of	predominantly	English	and	Irish	decent	(Parfrey,	Davidson,	&	Green,	2002).	Mating	segregation,	combined	with	low	immigration,	and	geographical	isolation	of	communities	resulted	in	the	genetic	isolation	of	the	population	(Young	et	al.,	1999).	When	a	limited	number	of	individuals	bring	a	disease	mutation	into	a	small	population,	the	population	grows	through	natural	expansion	and	(in	the	absence	of	significant	in-migration)	a	high	proportion	of	people	will	carry	the	chromosome	on	which	a	disease	mutation	is	found	(Rahman	et	al.,	2003).	Opposite	to	a	founder,	or	inbred,	population	is	an	outbred	population.	This	involves	normal	genetic	variation,	as	mating	more	often	occurs	with	those	who	have	no	familial	relations.	Ontario	(ON)	is	an	example	of	this	type	of	population	as	it	geographically	central,	non-isolated,	with	normal	immigration	rates.	
A	founder	effect	has	been	observed	in	NL	for	many	genetic	disorders	One	such	disease	is	arrhythmogenic	right	ventricular	cardiomyopathy/dysplasia	(ARVC/D),	a	known	cause	of	SCD,	resulting	from	one	genetic	subtype	of	which	is	caused	by	a	
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mutation	in	the	transmembrane	protein	43	(TMEM43)	gene.	This	mutation	(c.1073	C>T.pS358L),	discovered	by	our	laboratory	(Merner	et	al.,	2008),	changes	the	amino	acid	serine	to	the	amino	acid	leucine	at	position	358.	This	mutation	is	fully	penetrant;	it	will	show	clinical	signs	of	the	disease	over	the	lifespan	in	everyone	who	carries	the	gene	mutation.	The	exact	incidence	of	the	mutation	in	NL	is	unknown,	but	likely	>1/1000	persons	(K.	Hodgkinson,	personal	communication,	September	25th,	2014).	We	also	know	that	there	are	other	founder	mutations	(RYR2	(p.R176L)	and	
PCP2	(p.Q378X))	causing	other	types	of	cardiomyopathies	and	channelopathies	that	are	responsible	for	young	SCD	in	several	large	cohorts	in	NL	(Hodgkinson	et	al.,	2013;	Lauson	et	al.,	2014).	Given	the	known	mutations,	we	hypothesize	that	NL	has	a	higher	incidence	of	early	SCD	than	elsewhere	in	Canada.		
Incidence	and	prevalence	are	both	measures	of	the	extent	of	disease	in	a	population.	Incidence	is	the	rate	of	new	cases	of	the	disease	among	the	population.	Prevalence	includes	both	new	cases	and	those	who	have	contracted	the	disease	in	the	past	and	are	still	surviving.	With	respect	to	SCD,	we	are	more	interested	in	measuring	the	incidence,	as	prevalence	is	not	applicable	because	SCD	is	not	a	curable	disease,	no	one	can	survive	it.	
Accurate	incidence	data	has	not	been	easy	to	collect,	as	there	is	no	general	population	SCD	genetic	screening	available	in	NL.	Genetic	screening	involves	testing	an	individual’s	deoxyribonucleic	acid	(DNA)	for	multiple	known	gene	mutations.	In	comparison,	clinical	screening	involves	using	diagnostic	tests	(such	as	
	 5	
electrocardiogram,	or	echocardiogram)	to	look	for	phenotypic	changes.	Clinical	screening	is	not	very	effective	for	SCD,	as	we	have	not	found	any	precise	markers	yet.	Genetic	screening,	however,	can	be	quite	helpful	in	preventing	SCD	depending	on	the	gene	mutation	we	are	dealing	with.	
Many	ethical	issues	arise	when	debating	whether	there	should	be	genetic	screening	available,	for	example	as	part	of	newborn	screening.	Factors	to	consider	include	cost	implications	for	the	health	care	system,	potential	clinical,	financial,	and	emotional	consequences	with	false-positive	screening	results	for	the	patients,	and	as	well,	the	current	lack	of	evidence-based	guidelines	to	deal	with	management	of	asymptomatic	patients	who	screen	positive	(Kaltman	et	al.,	2011).	As	such,	health	care	professionals	are	not	prepared	to	fully	deal	with	general	population	genetic	screening.	Unfortunately,	young	SCD	is	one	of	those	cases	where	clinical	screening	compared	to	genetic	screening	is	not	effective,	as	SCD	can	present	with	no	prior	symptoms	acting	as	a	warning.	This	makes	it	important	to	identify	which	individuals	are	at	greatest	risk	of	preventable	early	SCD	in	order	to	offer	prophylactic	medications	or	devices,	such	as	the	implantable	cardioverter-defibrillator	(ICD)	(Kauferstein	et	al.,	2009).		
1.1	Literature	Search	
	 A	comprehensive	literature	search	of	numerous	relevant	medical	databases	(Pubmed	and	meSH,	EMBASE,	CINAHL,	Google	Scholar,	and	Scopus)	was	performed	to	fully	understand	the	scope	of	young	SCD.	This	was	accomplished	using	various	
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combinations	of	the	key	words:	“sudden	cardiac	death”	“sudden	unexpected	death”	“young”,	“genetics”,	“epidemiology”,		“arrhythmogenic	right	ventricular	cardiomyopathy”,	“arrhythmogenic”,	“arrhythmia”,	”cardiomyopathy”,	“channelopathy”,	and	“non-genetic”.	Reference	lists	of	relevant	papers	were	also	surveyed	to	identify	additional	literature	on	topics	of	interest.	
1.2 Describing	Sudden	Cardiac	Death		
Once	SCD	is	diagnosed,	there	are	more	questions	to	answer.	SCD	is	defined	as	the	unexpected	natural	death	from	a	cardiac	cause	within	a	short	time	period,	generally	≤	1	hour	from	the	onset	of	symptoms,	in	a	person	without	any	prior	potentially	fatal	condition	(Zipes	&	Wellens,	1998).	Physiologically,	SCD	often	occurs	when	an	electrically	stable	heart	is	transformed	into	an	unstable	one,	causing	a	fatal	arrhythmia.	The	exact	cause	of	this	transformation	is	richly	diverse,	as	SCD	is	the	final	common	end	point	of	multiple	disease	processes;	it	results	from	a	complex	interplay	of	structural,	metabolic,	and	genetic	determinants	(Noseworthy	&	Newton-Cheh,	2008).	
SCD	is	a	heterogeneous	condition;	CAD	accounts	for	about	80%	of	SCDs,	and	the	remaining	20%	is	attributed	to	cardiomyopathies	and	genetic	diseases	(Chugh	et	al.,	2008).	To	complicate	the	matter,	other	medical	conditions,	such	as	diabetes	(Jouven,	2005),	as	well	as	more	dynamic	associations,	such	as	low	socioeconomic	status	(SES),	are	also	associated	with	SCD	(Chugh	et	al.,	2008)	(Figure	1.1).		The	age	range	for	SCD	is	wide	as	it	occurs	in	individuals	of	all	ages,	from	ages	2	and	beyond.	As	age	
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varies,	etiology	of	the	disease	may	vary	as	well;	CAD	is	more	prevalent	in	the	older	population,	and	genetic	conditions	can	exert	their	effects	at	any	age	–	young	and	old.	All	in	all,	it	is	clear	that	overall	incidence	of	SCD	increases	with	age	(Deo	&	Albert,	2012).		
With	regard	to	gender,	SCD	has	a	much	higher	incidence	in	men	than	women	(Deo	&	Albert,	2012;	Zipes	&	Wellens,	1998).	Analysis	of	the	Framingham	Heart	Study	cohort	showed	that	at	age	40	the	lifetime	risk	of	SCD	for	men	is	1	in	8,	while	women	are	three	times	less	likely	(1	in	24)	(Lloyd-Jones,	Berry,	Ning,	Cai,	&	Goldberger,	2009).		While	this	reflects	sex	differences	in	the	incidence	of	CAD,	a	higher	incidence	in	men	has	been	observed	in	other	genetic	causes	of	SCD	as	well.	Australian	researchers	studied	SCD	in	a	cohort	with	age	less	than	35	years	and	found	that	63%	of	subjects	were	male	when	CAD	was	excluded	(Doolan,	Langlois,	&	Semsarian,	2004).	In	hypertrophic	cardiomyopathy	(HCM)	both	sexes	are	affected	by	the	condition,	though	it	is	more	likely	to	be	detected	earlier	in	men	(Christiaans	et	al.,	2011;	Jacoby,	Depasquale,	&	McKenna,	2013).	In	a	study	that	evaluated	the	largest	population	of	patients	with	Brugada	syndrome	(BrS)	thus	far,	they	reported	that	men	had	a	5.5-fold	higher	risk	of	sudden	death	than	did	women	(Brugada,	Brugada,	&	Brugada,	2003).	
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Figure	1.1:	The	Determinants	of	SCD.		
While	cardiac	conditions,	environment,	and	comorbidities,	contribute	their	own	influence	(red	arrows),	these	factors	also	are	affected	by	one	another	(blue	dashed	arrows).	Adapted	from	Chugh	et	al.,	2008.	
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Other	studies	corroborate	that	men	with	BrS	present	with	a	greater	risk	clinical	profile	than	women	and	have	a	worse	prognosis	(Benito	et	al.,	2008).	In	ARVC/D,	multiple	studies	have	identified	it	to	be	a	male-predominant	disease	(Cox	et	al.,	2011;	Merner	et	al.,	2008),	however	there	are	also	reports	of	equal	numbers	between	the	sexes	(Dalal,	2005).		
Given	the	wide	variety	of	causes	of	SCD,	there	is	no	specific	symptom	set	for	the	condition.	Having	said	that,	symptoms	that	are	typical	of	any	heart	disease	have	been	associated	with	SCD,	such	as	syncope,	dyspnea,	and	heart	palpitations.	Tragically,	it	is	not	unusual	for	the	very	first	symptom	of	conditions	causing	SCD	to	be	death	itself.	It	is	for	this	reason	that	SCD	takes	such	a	heavy	toll	on	families	and	communities.	
Fortunately,	not	all	individuals	at	risk	of	SCD	are	asymptomatic.	By	tracing	family	health	history	and	genetic	testing	a	preventative	therapy	can	be	put	in	place.	Treatments	for	conditions	that	increase	the	risk	of	SCD	are	similar.	The	therapeutic	course	will	depend	on	symptoms	-	previous	cardiac	arrest	or	arrhythmia.	Standard	therapeutic	options	include	anti-arrhythmic	drugs,	an	ICD,	cardiac	pacing,	or	catheter	ablation.	For	heart	failure,	the	ICD	is	primary	standard	of	care	(along	with	anti-heart	failure	medications)	when	the	patient	has	high-risk	indicators,	such	as	left	ventricular	dysfunction	or	reduced	left	ventricular	ejection	fraction,	or	heart	failure	symptoms	(Marine	&	Russo,	2014a,	2014b).	Evidence	has	shown	that	the	ICD	is	the	better	option	for	treatment	of	heart	failure	when	compared	with	anti-arrhythmic	
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drugs.	Anti-arrhythmics	are	not	often	prescribed	on	their	own,	but	more	often	as	adjunctive	therapy	with	the	ICD.	Catheter	ablation	is	also	an	option	for	when	the	ICD	is	not	indicated.	Cardiomyopathies	(HCM,	ARVC/D	and	dilated	cardiomyopathy	(DCM))	have	similar	treatments,	with	the	ICD	being	the	gold	standard	for	high-risk	patients	(Elliott	&	McKenna,	2014;	McKenna,	2014).	The	difference	here	is	that	prophylactic	treatment	can	be	started	in	asymptomatic	patients	when	identified	as	high	risk	due	to	family	history	(McKenna,	2014).	The	ICD	efficacy	was	examined	in	11	families	with	the	TMEM43	mutation	in	NL	and	the	five-year	mortality	rate	after	ICD	in	males	was	zero	compared	with	28%	in	control	subjects	(p<	0.009)(Hodgkinson	et	al.,	2005).	For	channelopathies,	BrS,	long	QT	syndrome	(LQTS)	and	catecholaminergic	polymorphic	ventricular	tachycardia	(CPVT)),	the	ICD	is	the	superior	treatment	though	may	not	be	the	first	line.	Commonly,	Beta-blockers	are	the	mainstay	of	therapy	unless	there	are	frequent	associated	symptoms	(Buxton,	2014;	Wylie	&	Garlitski,	2014;	Zimetbaum,	Seslar,	Berul,	&	Josephson,	2014).		
	 Many	young	SCD’s	still	occur	despite	the	effectiveness	of	the	ICD	and	drug	therapy,	as	identifying	candidates	clinically	for	therapy	can	be	difficult.	Furthermore,	genetic	screening	programs	for	SCD-causing	conditions	are	not	yet	effectively	used	(Kaltman	et	al.,	2011)	.	Research	has	not	brought	us	to	the	level	of	proficient	preventative	medicine	just	yet,	and	thus,	SCD	is	an	unyielding	burden.	
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1.3 	Genetic	Etiology		
While	CAD	accounts	for	the	majority	of	SCDs,	the	rest	can	likely	be	attributed	to	genetic	causes,	which	includes	nonischemic	myopathic	processes,	such	as	cardiomyopathies,	and	primary	defects	of	cardiac	electrophysiology,	such	as	LQTS	(Noseworthy	&	Newton-Cheh,	2008).	Many	of	these	conditions	show	mendelian	inheritance,	also	called	monogenic,	patterns.	Mendelian	inheritance	is	a	description	of	the	way	traits	are	passed	down	from	one	generation	to	another	–	and	sometimes	skips	generations-	as	a	result	of	a	mutation	in	one	single	gene	(Miko,	2008).	There	are	multiple	possible	patterns	of	inheritance	that	can	be	located	on	an	autosome	or	on	a	sex	chromosome,	and	the	disease	phenotype	is	described	as	being	dominant	or	recessive	(Chial,	2008).	In	cardiac	genetics,	many	diseases	display	an	autosomal	dominant	or	autosomal	recessive	pattern	(Table	1.1).	Autosomal	dominant	diseases	occur	in	individuals	who	have	a	single	mutant	copy	of	the	disease-associated	gene,	and	can	be	inherited	from	an	affected	mother	or	father.	Thus,	this	mutation	will	be	passed	down	to	all	future	generations.	Autosomal	recessive	diseases	occur	in	individuals	with	two	mutant	alleles	of	the	disease-associated	gene.	These	individuals	must	inherit	one	mutant	allele	from	each	of	their	parents.	Autosomal	recessive	single-gene	diseases	often	show	a	pattern	which	the	disease	‘skips’	one	or	more	generations	(Chial,	2008).	
Observations	of	SCD	incidence	in	families	show	a	clear	role	for	genetics.	For	example,	in	an	Israeli	case-control	study	of	SCD	patients,	a	family	history	of	SCD	was		
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Cardiac	Disease	 Gene	 Locus	 Protein	 Mode	of	
Inheritance	
Frequency	in	
Patients	
Hypertrophic	
Cardiomyopathy	
TNNT2	 1q32	 cardiac	troponin	T	 Autosomal	dominant	 3-5%	MYBPC3	 11p11.2	 cardiac	myosin-binding	protein	C	 Autosomal	dominant	 25-25%	MYH7			 14q11.2-q12	 β-myosin	heavy	chain	 Autosomal	dominant	 25-25%	
Arrhythmogenic	
Right	Ventricular	
Cardiomyopathy/	
Dysplasia	
TMEM43	 3p25	 transmembrane	protein	43	 Autosomal	dominant	 rare*	DSP	 6p24	 desmoplakin	 Autosomal	dominant	 10-20%	DSG2	 18q12.1-q12.2	 desmoglein	2	 ?Autosomal	dominant	 10-15%	
Dilated	
Cardiomyopathy	
DMD	 Xp21.2	 dystrophin	 X-linked	 ?	DES	 2q35	 desmin	 Autosomal	dominant	 ?	TNNI1	 1q12	 cardiac	troponin	I	 Autosomal	dominant	 ?	
Long	QT	Syndrome	 KCNQ1	 11p15.5	 Kv7.1	 Autosomal	dominant,	or	recessive	 30-35%	SCN5A	 3p21-p24	 NaV1.5	 Autosomal	dominant	 5-10%	ANKB	 4q25-q27	 ankyrin	B	 Autosomal	dominant	 rare*	
Catecholaminergic	
Polymorphic	
Ventricular	
Tachycardia	
CASQ2	 1p13.3	 calsequestrin	2	 Autosomal	recessive	 rare*	RYR2	 1q42.1-q43	 ryanodine	receptor	2	 Autosomal	dominant	 50-60%	
Brugada	Syndrome	 SCN5A	 3p21-p24	 NaV1.5	 Autosomal	dominant	 20-30%	GPD1L	 3p22.3	 glycerol-3-phosphate	dehydrogenase	1-like	 Autosomal	dominant	 rare*	CACNA1C	 2p13.3	 l-type	calcium	channel	 Autosomal	dominant	 ?	
Table	1.1:	Examples	of	a	genetic	basis	for	structural	and	arrhythmogenic	cardiac	diseases.		Adapted	from	Tester	&	Ackerman	(2009)	and	Jeffries	&	Towbin	(2010).	*:	These	frequencies	may	be	underestimating	true	numbers.	This	table	of	gene	mutations	can	cause	SCD,	and	thereby	remove	subjects	from	the	patient	count.	“Frequency	in	patients”	refers	to	alive	patients,	possible	ascertainment	bias	here.	See	Appendix	A	for	full	list	of	known	cardiac	mutations.	
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associated	with	a	46%	increased	risk	of	SCD	compared	with	matched	controls	(relative	risk=1.5)(Friedlander	et	al.,	1998).	In	the	Paris	Prospective	Study	I,	a	parental	history	of	SCD	increased	the	risk	of	fatal	arrhythmia	in	the	offspring	by	80%;	in	subjects	with	both	parents	affected,	risk	of	individuals	with	an	established	SCD	syndrome,	a	family	history	can	potentiate	risk	of	SCD.	For	example,	in	HCM,	a	family	history	of	SCD	is	associated	with	a	5-fold	increase	for	risk	of	SCD	(Elliott	et	al.,	2000).	This	is	likely	due	to	the	underlying	pathogenicity	of	the	mutation,	each	mutation	with	different	clinical	picture-	which	can	even	occur	with	mutations	in	the	same	gene	(allelic	heterogeneity)	hence	the	importance	of	studies	examining	mutation	variations.	
	The	current	known	genetic	conditions	are	broken	into	two	groups,	structural	and	arrhythmogenic.	Structural	diseases,	which	are	more	easily	detected	via	autopsy,	include	HCM,	DCM,	and	ARVC/D-	although,	these	can	present	early	in	its	course	with	no	obvious	structural	anomalies.	The	arrhythmogenic	diseases,	often	referred	to	as	channelopathies,	tend	to	be	missed	at	autopsy	because	they	cause	no	structural	changes	to	the	heart.	This	category	includes	BrS,	CPVT,	LQTS,	and	short	QT	syndrome	(SQTS)	(Figure	1.2).	
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Figure	1.2:	Categories	of	heart	diseases	where	genes	have	been	found	to	be	involved,	divided	into	cardiomyopathies,	CAD,	and	channelopathies.	*Rare	–	not	discussed	in	dissertation		
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1.3.1 Structural	Diseases	
Structural	abnormalities	of	the	heart	are	a	significant	result	of	genetic	heart	disorders	(Ingles	&	Semsarian,	2007).	The	structural	abnormalities	that	result	are	not	identical	across	diseases,	but	typically	compromise	the	structure	of	the	right	or	left	ventricle,	possibly	through	fat	deposition,	hypertrophy,	or	dilatation.	These	abnormalities	can	go	undetected	throughout	an	individual’s	life,	and	may	only	be	diagnosed	after	SCD	and	a	meticulous	autopsy.	Defining	the	exact	burden	of	SCD	due	to	these	cardiomyopathies	is	a	challenging	task.	Overall,	the	contribution	to	SCD	caused	by	cardiomyopathies	differs	with	disease;	ARVC/D	is	ranked	the	highest,	followed	by	HCM,	and	then	DCM	(Sen-Chowdhry	&	McKenna,	2012).	
DCM	is	the	most	common	cardiomyopathy	worldwide,	characterized	by	dilatation	and	impaired	contraction	of	the	left	or	both	ventricles	(Jefferies	&	Towbin,	2010).	The	natural	history	of	DCM	is	for	patients	to	present	with	heart	failure	or	an	arrhythmia;	heart	failure	or	an	arrhythmic	event	can	lead	to	SCD	(Sen-Chowdhry	&	McKenna,	2012).	
HCM	is	a	commonly	inherited	cardiomyopathy,	defined	by	the	presence	of	left	ventricular	hypertrophy	in	the	absence	of	abnormal	loading	conditions,	such	as	hypertension	(Jacoby	et	al.,	2013).	The	myocardial	hypertrophy	can	cause	numerous	outcomes	that	may	lead	to	SCD,	for	example,	obstruction	of	the	left	ventricular	outflow	tract,	atrial	fibrillation,	and	ventricular	arrhythmias	(Elliott	&	McKenna,	2004).	
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Arrhythmogenic	right	ventricular	cardiomyopathy/dysplasia	(ARVC/D)	is	a	heritable	cardiomyopathy	whereby	patients	demonstrate	a	fibrofatty	replacement	of	the	myocardium	of	the	right	ventricle	(RV)	(Thiene,	Nava,	Corrado,	Rossi,	&	Pennelli,	1988).	The	loss	of	healthy	myocardium	increases	risk	of	arrhythmia,	which	may	cause	SCD.	All	of	these	cardiomyopathies	involve	a	genetic	component,	meaning	they	are	often	caused	by	a	genetic	mutation.	As	seen	in	Table	1.1	(and	Appendix	A),	there	are	multiple	genetic	mutations	per	condition,	all	affecting	a	different	protein	that	alters	the	function	of	the	heart.	For	example,	ARVC	can	be	caused	by	a	mutation	in	TMEM43,	desmoplakin,	desmoglein	2	etc.,	all	of	which	have	different	frequencies	in	different	populations.	
1.3.2	Arrhythmogenic	Diseases	
Arrhythmogenic	heart	conditions	are	not	anatomically	apparent	in	the	heart,	as	they	operate	on	a	non-structural	level.	Given	the	physical	subtleness	of	these	conditions,	assessing	the	true	burden	is	quite	difficult.	To	illustrate,	a	2001	Italian	study	examining	young	SCD	victims	(≤35	years	of	age)	found	that	16	subjects	(6%)	died	with	an	apparently	normal	heart,	and	the	cause	of	SCD	unexplained	(Corrado,	Basso,	&	Thiene,	2001).	It	is	these	cases	of	SUD,	or	studies	that	cannot	explain	SCD,	that	likely	etiology	may	be	a	type	of	channelopathy.		
BrS	is	an	arrhythmic	syndrome	characterized	by	increased	risk	for	sudden	death	resulting	from	episodes	of	polymorphic	ventricular	tachyarrhythmia’s	(Chen	&	Priori,	2008).	CPVT	is	another	heritable	arrhythmia	that	typically	manifests	with	
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exertional	syncope	or	sudden	death	(Priori,	2002).	LQTS	is	a	type	of	channelopathy	that	involves	delayed	repolarization	of	the	myocardium,	resulting	in	an	increased	risk	of	an	arrhythmia	and	thus	SCD	(D.	Tester	&	Ackerman,	2009).	SQTS,	a	more	recently	recognized	clinical	syndrome,	is	the	opposite	of	LQTS	in	that	it	involves	a	short	QT	interval	which	increases	risk	of	SCD	(D.	Tester	&	Ackerman,	2009).	Again,	all	of	these	conditions	significantly	involve	a	genetic	component	(Table	1.1	&	Appendix	A).	
1.4 	Non-Genetic	Etiology		
As	previously	mentioned,	SCD	is	the	result	of	a	complex	interplay	of	multiple	factors	–	not	all	are	genetic.	Firstly,	there	are	medical	conditions	that	can	cause	or	contribute	to	SCD.	Diabetes	mellitus	is	a	significant	risk	factor	for	SCD,	proven	in	multiple	studies,	including	the	Paris	Prospective	Study	I,	which	found	through	multivariate	analysis	that	diabetes	independently	conferred	a	significant	risk	for	SCD	(relative	risk=	2.64,	95%	confidence	interval=	1.26–5.53)	(Jouven,	Desnos,	Guerot,	&	Ducimetiere,	1999).	Other	comorbidities	included	in	the	equation	are	smoking	and	obesity,	often	due	to	a	lack	of	physical	activity	and/or	diet.	These	environmental	factors	have	already	been	proven	to	have	a	negative	impact	on	cardiac	health	by	increasing	risk	of	CAD,	and	thus	SCD.	A	recent	case-control	study	on	firemen	≤	45	years	old	found	that	of	the	87	SCD	victims,	63%	were	obese	and	67%	had	CAD	(Yang	et	al.,	2013).	Cardiomegaly	was	also	found	in	66%	of	victims	and	this	was	associated	with	five-fold	increased	risk	of	SCD	(Yang	et	al.,	2013).	As	
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well,	hypertension	was	associated	with	a	12-fold	increased	risk	of	SCD,	and	smoking	and	cardiovascular	disease	showed	to	be	independent	risk	factors	for	SCD	(Yang	et	al.,	2013).	Finally,	another	environmental	factor	that	ties	all	of	this	together	is	low	SES.	In	the	ongoing	Oregon	Sudden	Unexpected	Death	Study,	a	2-year	prospective	evaluation	of	the	potential	relationship	between	SES	and	occurrence	of	SCD	was	performed	(Reinier	et	al.,	2006).	This	investigation	included	all	cases	of	SCD	in	a	large	urban	and	suburban	US	county	(population	of	670,000).	Incidence	of	SCD	based	on	address	of	residence	was	30%	to	80%	higher	among	residents	of	neighborhoods	in	the	lowest	SES	quartile	compared	to	neighborhoods	in	the	highest	SES	quartile.	However,	the	study	did	not	correct	for	any	additional	possible	confounding	factors	(such	as	smoking,	obesity,	diabetes	etc.),	and	therefore	it	is	difficult	to	comment	on	the	validity	of	the	SES-SCD	relationship.	While	it	remains	unexplored	to	the	fullest	extent,	it	is	clear	there	will	always	be	multiple	environmental	factors	at	work.	
There	are	other	non-genetic	causes	that	could	act	as	a	more	direct	trigger	of	SCD,	such	as	alcohol	consumption,	physical	activity,	or	a	viral	infection.	Alcohol	has	long	been	known	to	be	the	culprit	of	cardiac	arrhythmias	amongst	heavy	drinkers,	for	example	by	causing	an	atrial	fibrillation	the	heart	cannot	get	out	of	on	its	own	(Koskinen,	Kupari,	Leinonen,	&	Luomanmaki,	1987).	The	relationship	between	alcohol	and	arrhythmias	is	complicated	and	controversial,	dependent	on	many	factors,	such	as	gender,	age,	amount	of	alcohol	consumed,	and	whether	or	not	an	individual	is	alcohol	dependent	(Wannamethee,	Shaper,	Macfarlane,	&	Walker,	
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1995).	For	certain,	arrhythmias	due	to	alcohol	do	occur,	most	commonly	via	atrial	fibrillation,	but	other	mechanisms	are	possible,	such	as	ventricular	tachycardia	(George	&	Figueredo,	2010)	.	Physical	activity	has	been	under	suspicion	by	many	as	a	trigger	for	SCD,	as	SCD	is	a	common	cause	of	death	in	athletes;	however,	recent	studies	have	shown	that	the	majority	of	SCD	victims	died	while	sedentary	(Chugh	et	al.,	2008;	Reddy	et	al.,	2009).	These	studies	have	looked	at	SCD	in	the	general	population,	and	have	not	accounted	for	which	victims	were	athletes,	therefore	these	data	does	not	speak	to	the	relationship	of	SCD	and	athletes,	but	more	so	to	the	average	individual.	Finally,	a	very	serious	and	proven	cause	of	SCD	is	a	bacterial	infection,	such	as	infective	endocarditis	(Thuny	et	al.,	2013).	
All	of	these	factors	could	possibly	cause	SCD,	or	could	also	interact	with	underlying	genetic	mutations	to	cause	a	disease	phenotype.	While	non-genetic	factors,	such	as	obesity,	smoking,	hypertension	etc.,	indisputably	play	a	role	in	SCD,	the	majority	of	them	will	take	effect	in	an	older	aged	population,	that	is	to	say	that	for	young	SCD	these	factors	have	less	impact,	but	as	middle	age	nears	they	likely	play	a	bigger	role.		
1.5	Characterized	Populations	Dealing	with	Young	SCD	
There	are	a	number	of	studies	that	have	examined	the	causes	of	young	SCD	in	specific	populations.	Current	literature	suggests	there	is	significant	mortality	associated	with	genetic	cardiac	disorders.	A	study	completed	in	2004	by	Doolan	et	al.	analyzed	sudden	deaths	in	Australian	subjects	(≤35	years	of	age)	that	occurred	
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from	1994-2002	(Doolan	et	al.,	2004).	In	total,	there	were	193	deaths	classified	as	SCD.	These	deaths	were	caused	by	CAD	(24%),	HCM	(15%),	congenital	heart	disease	(7%),	a	group	classified	as	‘other’	which	included	aortic	dissection	and	valvular	heart	disease	(11%),	and	a	group	with	no	structural	anomalies	thus	presumed	arrhythmic	(31%).	In	this	very	young	cohort,	there	is	likely	a	genetic	component	at	play,	as	a	third	of	the	deaths	have	no	structural	issues	at	all.		
								A	2001	Italian	study	by	Corrodo	et	al.	examined	273	subjects	who	had	suffered	SCD	(≤35	years	of	age)	with	apparently	normal	hearts	(Corrado	et	al.,	2001).	The	hearts	of	the	subjects	were	analyzed	using	a	detailed	protocol	that	included	both	histological	and	macroscopic	analysis.	They	found	72%	of	the	victims	had	an	underlying	cardiac	abnormality,	such	as	a	cardiomyopathy	or	CAD.	The	remaining	28%	had	a	macroscopically	normal	heart;	however,	upon	further	histologic	examination	79%	of	these	cases	revealed	concealed	pathologic	substrates	such	as	ARVC/D	and	focal	myocarditis.	A	total	of	16%	showed	neither	macroscopic	nor	histologic	abnormalities	leaving	the	mechanism	of	SCD	unexplained.	There	is	no	mention	of	blinding	in	this	study	for	the	pathologists,	which	is	a	significant	potential	for	bias.	There	was	a	control group	of	20	hearts	from	age-	and	sex-matched	subjects	who	died	suddenly	of	drug	abuse	or	extra-cardiac	causes.	None	of	the	control	hearts	exhibited	significant	coronary,	myocardial,	valve,	or	conduction	system	abnormalities.	This	particular	study	again	highlights	that	there	are	possibly	genetic	abnormalities	present,	or	environmental	exposures	that	have	left	no	trace.	
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Tragically,	there	are	always	cases	where	no	evidence	of	SCD	is	present,	aside	from	the	death,	which	typically	leads	to	a	misdiagnosis	of	cause	of	death.		
								A	study	published	in	2011	by	Eckart	et	al.	reported	on	the	incidence	and	nature	of	sudden	death	in	a	large	but	select	group	of	United	States	military	recruits	(Eckart	et	al.,	2011).	They	identified	902	predominantly	male	subjects	(mean	age	38	+/-	11	years)	for	whom	the	cause	of	death	was	of	potential	cardiac	etiology.	Sudden	death	was	attributed	to	a	cardiac	condition	in	79%	and	was	unexplained	in	21%.	From	reviewing	the	literature	it	is	clear	that	there	is	a	common	trend	of	high	rates	of	young	SCD	mortality.	
	 						In	Canada,	only	two	studies	have	been	completed	looking	at	SCD	incidence	in	the	young.	One	study	by	Lim	et	al.	(2010)	in	British	Columbia	found	an	incidence	of	SUD,	in	ages	0-35,	of	3.07	per	100,000	per	year,	and	1.75	per	100,000	per	year	of	SCD,	demonstrating	there	is	indeed	a	large	burden	associated	with	young	sudden	death.	More	recently,	Pilmer	et	al.	(2013)	completed	a	study	for	the	year	2008	in	ON,	examining	the	scope	and	nature	of	SCD	in	ages	2-40.	They	found	that	incidence	of	SCD	increased	with	age,	and	those	below	age	30	are	more	likely	to	suffer	from	a	primary	arrhythmia	syndrome	(odds	ratio=	2.97,	p<.	001).	These	Canadian	studies	show	that	young	SCD	is	a	relevant	issue	here,	though	more	research	is	needed	to	fully	characterize	the	issue,	as	Canada	is	a	genetically	diverse	population.	
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1.6 	Newfoundland	and	Labrador	(NL):	A	Founder	Population	
In	2008,	Merner	et	al.	identified	a	genetic	mutation	in	patients	and	extended	relatives	from	15	unrelated	families	with	Newfoundland	ancestry-	in	TMEM43	gene	that	causes	autosomal	dominant	ARVC/D.	This	mutation	(p.S358L)	changes	the	amino	acid	serine	to	the	amino	acid	leucine	at	position	358.	Our	team	showed	that	the	clinical	consequence	of	harboring	the	TMEM43	mutation	is	early	SCD	(50%	of	untreated	males	deceased	by	40	years,	80%	by	50	years)(Merner	et	al.,	2008).	Treatment	for	ARVC/D	using	the	ICD	is	a	very	effective	treatment	method	if	the	mutation	or	heart	condition	is	known	(Hodgkinson	et	al.,	2005).		Although	it	is	currently	known	that	this	mutation	is	present	in	the	NL	population,	the	determination	of	its	physical	effect	comes	from	the	ascertainment	of	families	manifesting	early	SCD.	We	do	not	currently	know	the	exact	incidence	of	the	p.S358L	mutation	in	the	population,	and	ongoing	studies	aim	to	determine	the	answer.	We	do	know,	however,	that	a	multitude	of	genetic	mutations	are	causing	cardiac	problems	in	the	NL	populations	as	currently	the	Cardiac	Genetics	Clinic	under	Eastern	Health	in	St.	John’s,	NL	has	been	referred	649	families	with	various	cardiac	conditions.	The	condition/reason	for	referral	with	the	highest	number	of	families	is	SCD	(K.	Hodgkinson,	personal	communication,	September	25th,	2014).		
From	an	environmental	risk	factor	point	of	view,	NL	is	on	the	high	end	of	the	spectrum	when	it	comes	to	risk	of	heart	disease	(Asghari	et	al.,	2015;	Filate,	Johansen,	Kennedy,	&	Tu,	2003).	When	it	comes	to	obesity,	a	recent	study	showed	
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NL	to	be	the	‘heaviest’	province	in	Canada,	and	projected	this	to	be	the	trend	for	the	future	(Twells,	Gregory,	Reddigan,	&	Midodzi,	2014).	While	obesity	itself	is	not	life	threatening,	the	sequelae	it	can	cause	are	highly	related	to	heart	disease	–hypertension,	diabetes	type	II,	CAD,	and	stroke	(Luo	et	al.,	2007).	NL	is	also	in	the	top	range	for	the	provinces	in	highest	percentage	of	smokers,	hypertension,	lack	of	physical	activity,	and	diabetes	(Statistics	Canada,	2014a).	All	of	these	factors	contribute	to	the	multifactorial	etiology	of	heart	conditions.	On	a	final	note,	while	environment	undoubtedly	plays	a	role	for	these	health	factors,	there	is	likely	a	genetic	component	involved	in	these	conditions	as	well.	Environment	is	not	solely	to	blame	as	some	factors,	such	as	hypertension	and	obesity,	have	a	genetic	component	as	well	(Bell,	Walley,	&	Froguel,	2005).	
1.7 	Medical	Examiner	Protocol	and	Reports	
The	duties	of	medical	examiners	are	relevant	to	this	project	as	the	data	is	collected	from	a	medical	examiner’s	database.	In	Canada,	medical	examiners	are	mandated	to	investigate	all	deaths	that	are	sudden,	unexpected,	or	from	non-natural	causes.	These	investigations,	completed	region-by-region,	answer	the	following	5	questions:	who	was	deceased;	how,	when	and	where	the	death	occurred;	and	by	what	means	the	death	occurred.	After	completion	of	the	investigation,	all	deaths	are	centralized	to	the	Office	of	Chief	Medical	Examiner	(OCME)	for	the	province.	
The	medical	examiner’s	report	includes	personal	information	and	results	from	the	medical	investigation–	date	of	death,	manner	of	death,	reported	cause	of	death,	
	 24	
environment	of	death,	as	well	as	a	narrative	section	that	includes	other	relevant	information	such	as	medical	history,	and	interviews	from	friends,	family,	or	eyewitnesses.	On	occasion,	when	circumstances	require	it,	police	reports	or	insurance	company	reports	are	also	in	the	report.	See	Appendix	B	for	a	sample	Medical	Examiner’s	report.	
1.8	Study	Rationale	and	Hypothesis	
The	scope	and	nature	of	SCD	in	NL	population	is	unknown.	One	study	from	ON	using	a	2008	cohort	assessed	the	incidence	of	SCD	in	persons	aged	2-40	years	old	to	be	2.64	per	100,000	(Pilmer	et	al.,	2013).		We	have	chosen	this	study	for	comparison	because	we	are	able	to	replicate	their	rigorous	methodology	for	the	exact	same	year	(2008).	As	well,	ON,	in	contrast	to	the	founder	population	in	NL,	is	a	large	Canadian	outbred	population,	thus	we	will	be	able	to	directly	compare	the	incidence	of	young	SCD	of	a	founder	population	(NL)	to	an	outbred	population	(ON).	We	hypothesize	that	NL	may	have	a	higher	incidence	of	early	SCD	in	this	age	category	due	to	the	known	mutations	causing	heart	diseases	and	unknown	underlying	genetic	causes,	given	the	historical	genetic	isolation	of	the	population.	We	hope	to	better	understand	the	scope	and	nature	of	SCD	in	NL	to	help	inform	health	policy,	therapy,	and	prevention.				
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1.9 	Study	Objectives	
The	objectives	of	this	study	are	to:	
1. Ascertain	the	number	of	SCDs	in	young	persons	(ages	2-40)	from	a	provincial	registry	of	medical	examiner-referred	sudden	deaths	in	2008.		2. Make	a	direct	comparison	with	ON,	a	comparably	more	outbred	population.	The	initial	analysis	will	focus	on	ages	2-40	then	we	will	add	ages	41-50	to	the	cohort,	as	we	know	that	many	deaths	due	to	TMEM43	occur	in	that	decade,	as	well	as	due	to	CAD.	3. 	Gather	data	for	ages	2-50	from	the	year	1997	–	a	year	before	the	ICD	was	an	available	treatment	in	NL	–	to	observe	any	SCD	rate	differences	with	2008	(a	year	where	treatment	was	readily	available	in	NL).	
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2.	Methods	
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2.1	Cohorts	of	Interest	I	collected	qualitative	data	on	the	years	2008	and	1997.	The	year	2008	is	significant	because	we	can	compare	our	data	to	an	ON	study	that	collected	data	from	the	year	2008	(Pilmer	et	al.,	2013).	For	comparison	with	our	2008	data,	we	collected	qualitative	data	from	1997	because	it	is	a	year	when	the	ICD,	an	effective	heart	disease	treatment,	was	not	available	for	insertion	in	NL.	This	is	in	comparison	to	2008,	when	the	ICD	was	readily	available	in	NL.		
The	age	groups	we	were	interested	in	are	2-40	and	2-50	years.	The	2-40	age	group	is	the	range	the	ON	study	used,	therefore	we	wanted	to	have	an	exact	comparison	group.	We	also	decided	to	collect	from	ages	41-50	because	we	know	that	many	SCDs	occur	in	this	age	range,	and	we	want	to	capture	the	full	spectrum	of	young	SCD.		
For	simplification	purposes,	I	will	refer	to	the	NL	2008	ages	2-40	as	cohort	A,	NL	2008	ages	2-50	as	cohort	B,	and	NL	1997	ages	2-50	as	cohort	C	(Table	2.1).	
2.2	Data	Collection	
	 This	epidemiologic	study	incorporated	a	retrospective	cohort	design,	with	an	emphasis	on	replicating	the	ON	study’s	methods	as	closely	as	possible	to	allow	us	to	directly	compare	with	their	results.	Qualitative	data	was	collected	on	276	cases.	Cases	of	potential	relevance	were	identified	from	the	database	of	the	OCME	of	NL	(Figure	2.1).	All	files	contained	a	medical	examiner’s	report,	and	an	autopsy		
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Table	2.1:		Labeling	of	the	cohorts	
Cohort	group	 Labeled	Cohort	NL	2008,	age	2-40	 A	NL	2008,	age	2-50	 B	NL	1997,	age	2-50	 C		
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Figure:	2.1:	Process	of	categorizing	deaths	and	assigning	to	category	of	SCD.	
	See	Tables	2.1	&	2	for	definitions	of	manners	of	death	and	categories	of	likeliness	of	SCD,	respectively.	Red	boxes	indicate	the	cases	we	assigned	as	SCD	and	thus	analyzed.	
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report	if	conducted.	Additional	information,	such	as	police	reports	or	reports	for	insurance	companies	were	available	depending	on	the	circumstances	of	the	death.	See	Appendices	B	and	C	for	a	sample	Medical	examiner’s	report	and	the	full	chart	audit	form.	SUD	was	defined	as	an	event	resulting	in	death	or	terminal	life	support	within	1	hour	of	collapse,	or	an	unwitnessed,	but	unexpected	death	in	the	absence	of	a	known	or	suspected	condition	that	may	predispose	to	terminal	illness	(Eckart	et	al.,	2011).	Deaths	were	further	defined	as	cardiac	in	origin	if	there	was	autopsy-confirmed	heart	disease	with	circumstances	consistent	with	a	potential	cardiac	cause	of	death.	SCD	was	also	declared	when	the	autopsy	showed	no	identifiable	cause	of	death,	and	it	was	therefore	presumed	a	cardiac	arrhythmia	took	place.	SUD	below	the	age	of	2	years	was	considered	a	separate	entity	and	was	not	included.	A	portion	of	cases	did	not	have	an	autopsy	completed,	and	SUD	was	then	classified	at	the	discretion	of	the	Chief	Medical	Examiner.		 Cases	of	potential	relevance	were	reviewed	by	myself	after	satisfying	3	inclusion	criteria:	(1)	date	of	death	in	2008	(same	year	as	ON)	or	1997,	(2)	age	at	death	between	2-40	or	41-50,	and	(3)	manner	of	death	(a	universal	pathologist	classification	method)	listed	as	“natural-cardiac”,	“natural-other”,	“accidental”	or	“undetermined”	(Table	2.2).	This	yielded	70	cases	for	2008	ages	2-40	and	49	cases	for	2008	ages	41-50	to	review.	For	1997,	this	yielded	90	cases	ages	2-40	and	67	cases	ages	41-50	to	review.	Considering	the	small	yield	of	number	of	subjects,	every	case	was	reviewed	in	detail.	Cases	that	were	not	sudden,	not	unexpected,	or	not	of		
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Table	2.2:	Manners	of	death	used	by	forensic	pathologists.	
Manner	 Definition	Natural	-	Cardiac	 Death	due	to	natural	disease	processes	in	cardiac	nature	Natural-	Other	 Death	due	to	natural	disease	processes	of	unknown	system	Accidental	 Death	due	to	injury	where	there	is	no	evidence	of	intent	to	harm	Undetermined	 Inadequate	information	regarding	circumstances	of	death	to	determine	manner		 	
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possible	cardiac	etiology	were	excluded	after	review.	For	example,	cases	were	excluded	when	cause	of	death	was	clearly	non-cardiac,	such	as	sepsis	or	pneumonia,	and	as	well	cases	involving	passengers	and	pedestrians	of	motor	vehicle	accidents,	and	house	fires.	Data	was	collected	on	all	276	cases,	which	were	considered	possible	SCDs.	These	data	included	demographic	information,	such	as	date	of	birth,	sex,	and	death	information	including	date,	location,	cause,	and	manner	of	death.	Autopsy	findings,	especially	related	to	cardiac	conditions,	were	noted,	as	was	any	known	history	of	cardiac	or	other	disease.	Cardiac	pathology	discovered	on	autopsy	was	listed	separately	from	any	known	preexisting	cardiac	conditions.	Since	the	files	did	not	contain	copies	of	the	individual’s	medical	charts,	previous	medical	conditions	were		noted	at	the	discretion	of	the	investigating	medical	examiner	and	abstracted	by	a	single	investigator.	Additional	data	collected	included	premonitory	symptoms,	nature	of	physical	activity	and	intensity	at	the	time	of	death,	medication	or	substance	use,	cardiac	risk	factors,	and	narrative	details	about	the	circumstances	of	death	from	the	available	evidence.	Premonitory	symptoms,	symptoms	within	24	hours	prior	to	death	and	also	prior	to	the	24	hours,	included	potential	cardiac	symptoms,	such	as	chest	pain,	shortness	of	breath,	and	syncope.	Physical	activity	level	at	the	time	of	death	was	determined	from	the	medical	examiner’s	narrative	and	was	classified	as	during	sleep,	at	rest,	during	light	to	moderate	activities	of	daily	living	(ADLs),	during	moderate	to	vigorous	exercise	or	unknown.	Subjects	were	classified	as	dying	at	rest	
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if	the	event	was	described	as	such	by	an	eyewitness	or	if	the	decedent	was	found	in	a	position	suggesting	rest.	Light	to	moderate	ADLs	included	activities	such	as	housework	and	other	nonphysically	strenuous	activities	such	as	driving.	Moderate	to	vigorous	exercise	included	any	sporting	or	fitness	activities	such	as	swimming	and	running,	as	well	as	any	strenuous	physical	work	or	chores	such	as	shoveling	snow.	Further	investigations	such	as	requests	for	additional	medical	records	or	personal	interviews	were	not	obtained	because	of	the	retrospective	nature	of	the	study.	
2.3	Likeliness	of	SCD	
	 After	I	collected	all	data,	each	case	was	reviewed	by	myself	and	an	expert	panel:	an	experienced	expert	in	genetic	cardiac	arrhythmias	(K.H.),	an	experienced	cardiac	genetic	counselor	(F.C.),	and	an	experienced	expert	in	cardiac	pathology	and	the	provincial	death	investigation	system	(S.A.,	Chief	Medical	Examiner,	Province	of	NL).	The	expert	panel	and	I,	using	the	same	system	as	ON,	categorized	each	subject	into	likeliness	of	SCD.	All	276	subjects	were	assigned	to	a	category	of	likelihood	of	SCD	by	reviewing	all	data	collected,	incorporating	information	from	across	the	file,	including	medical	cause	of	death,	underlying	pathology,	description	of	the	environment	and	circumstances,	and	contributing	factors	and	comorbidities	(Table	2.3).	The	first	category,	‘sudden	death’,	comprised	those	who	died	of	sudden	death	with	no	additional	factors	contributing	to	death	(ex.	alcohol,	toxicology,	hazardous	conditions)	(labeled	‘definite’-	Table	2.3).	This	group	also	included	those	who	had	only	one	contributing	factor,	other	than	cardiac	disease		
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Table	2.3:	Likeliness	of	SCD	categories.		
Categories	 Criteria	
Sudden	Death	 	
Definite	 SCD	with	no	additional	factors	
Probable	 SCD	with	1	potential	contributing	factor		 Examples:	24	year	old	male	died	during	nap	after	exercising,	28	year	old	male	found	in	bed	with	high	alcohol	level	(not	fatal	level)	
Possible	 Accidents	with	1	contributing	factor		 Example:	27	year	old	male	died	in	motor	vehicle	accident	in	icy	weather	
Unlikely	 Greater	than	1	contributing	factor		 Example:	49	year	old	male,	canoe	overturned,	no	life	jacket,	alcohol	involved		 	
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or	primary	arrhythmia	that	was	not	of	sufficient	gravity	to	have	caused	death	(labeled	‘probable’-	Table	2.3).	For	example,	an	individual	with	positive	toxicology	(non-lethal)	with	no	other	anatomical	cause	other	than	a	possibly	enlarged	heart	was	a	presumed	arrhythmia.	The	next	category,	‘possible	sudden	death’,	was	for	‘accidental’	cases	whereby	there	was	only	one	contributing	factor,	aside	from	the	accident.	In	essence,	this	category	hoped	to	capture	accidents	that	may	have	been	caused	by	an	arrhythmia.	To	note,	accidents	with	zero	contributing	factors	were	placed	in	the	‘probable’	group.	An	example	of	this	would	be	a	car	accident	with	no	logical	contributing	factors	(high	speed,	bad	weather,	alcohol,	etc.).	Finally,	the	last	category	was	‘unlikely’,	which	comprised	any	deaths	that	had	more	than	one	contributing	factor.	At	this	point,	we	moved	a	portion	of	the	‘unlikely’	s	to	an	exclusion	group	if	they	were	not	sudden,	not	unexpected,	or	not	of	possible	cardiac	etiology.	This	was	in	an	effort	to	keep	methodology	similar	to	the	ON	study.			 The	‘sudden	death’	category	was	further	broken	down	into	whether	the	SCD	was	caused	due	to	an	underlying	structural	heart	issue	or	no	anatomical	cause.	The	structural	cases	were	further	categorized	into	ischemic	and	non-ischemic.	Also	noted	was	whether	the	structural	cases	were	recognized	or	unrecognized	by	the	subject	prior	to	death	(Figure	2.1).	
2.4	Statistical	Analysis		 I	performed	all	statistical	analysis	using	SPSS	version	20.	Descriptive	statistics	were	completed,	and	the	Chi-square	test	was	used	with	the	addition	of	
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Fisher’s	exact	test	if	the	sample	size	was	small.		A	p-value	of	<.05	was	considered	significant.	
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3.	Results	
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3.1	Incidences		 In	the	2008	2-40	cohort	(A),	17	deaths	were	adjudicated	as	SCD	from	an	estimated	population	of	232,210	people	(Statistics	Canada,	2014b).	The	number	of	cases	in	comparison	with	the	ON	cohort	is	n=17	for	NL	vs.	n=174	for	ON,	shown	in	Figure	3.1	(Pilmer	et	al.,	2013).	Based	on	the	estimated	population,	the	incidence	in	NL	of	cohort	A	is	7.32/100,000	persons.	When	the	cohort	was	expanded	in	2008	to	those	aged	50	years	old	(B),	44	deaths	out	of	a	population	of	316,244	were	adjudged	to	be	SCD	(Figure	3.2),	giving	an	incidence	of	13.9/100,000	persons.	In	1997,	66	deaths	out	of	a	population	of	406,173	in	age’s	2-50	cohort	(C)	were	found	to	be	SCD	(Figure	3.2),	giving	an	incidence	of	16.23/100,000	persons.	The	incidences	for	each	cohort,	and	the	ON	cohort,	based	on	age	and	the	gender	breakdown	is	shown	in	Table	3.1	and	3.2.		See	Appendix	D	for	primary	data.		 Comparing	the	NL	cohort	A	to	the	ON	data,	NL	has	a	significantly	higher	incidence	of	SCD	than	ON	(p<.0001)	(Table	3.1).	When	comparing	age	groups	between	the	cohorts,	NL	becomes	significantly	higher	for	age	groups	19-29	and	30-40	(p=.028	&	p=.008,	respectively)	(Table	3.1).	There	is	also	a	clear	trend	here	that	SCD	increases	with	age.	There	is	a	gender	difference	in	the	NL	data,	as	the	cohort	is	65%	male.	While	this	may	present	some	issues	for	the	study,	ON	has	the	same	gender	bias	and	the	chi-square	comparing	NL	to	ON	gives	a	non-significant	difference	(Table	3.1).	Comparing	the	2008	NL	(B)	data	to	1997	NL	(C),	there	is	a	general	trend	of	more	SCDs	in	1997	but	it	is	a	non-significant	difference	(Table	3.2).			
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						NL	2008	Age	2-40	(A)	
		 	 	 	 	
		
Figure	3.1:	Review	of	all	potential	SCD	cases	in	NL	in	2008	age’s	2-40	(A)	in	comparison	to	ON	(2008,	age’s	2-40)	(Pilmer	et	al.,	2013).		
*:	Cases	with	no	autopsy	could	not	be	segregated	any	further	(n=1)		
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																																															NL	2008	and	1997	Age	2-50	(B	&	C)	
	
	
Figure	3.2:	Review	of	all	potential	SCD	cases	in	NL	2008	in	ages	2-50	cohort	(B),	in	comparison	to	NL	1997	age’s	2-50	cohort	(C).		
*:	Cases	with	no	autopsy	could	not	be	segregated	any	further	(n=10	for	2008,	n=14	for	1997)		 	
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Table	3.1:	Comparisons	of	incidence	and	gender	for	NL	2008	age’s	2-40	(A)	and	ON	2008	ages	2-40	(Pilmer	et	al.,	2013).	
*	=	Significant	difference,	p<.	05	†=	Fishers	exact	test	used,	expected	cell	count	<5	See	Appendix	D	for	primary	data			 NL	2008	2-40	(A)	 ON	2008	2-40	 Chi-square	value,	significance	(p-value)	
Incidences	Overall	 7.32/100,000	 2.64/100,000	 Χ2=	17.625,	p<.0001*	Ages	2-18	 2.15/100,000	 0.7/100,000	 Χ2=	2.418,	p=	.158†	Ages	19-29	 7.52/100,000	 2.4/100,000	 Χ2=	6.488	p=	.028*†	Ages	30-40	 13.74/100,000	 5.3/100,000	 Χ2=	8.929	p=.008*†	
Gender	Male	(%)	 65%	 76%	 Χ2=	1.024,	p=.379†		
	 	
	 42	
	
Table	3.2:	Comparisons	of	incidence	and	gender	for	NL	2008	age’s	2-50	(B)	and	NL	1997	age’s	2-50	(C).	
†=	Fishers	exact	test	used,	expected	cell	count	<5	See	Appendix	D	for	primary	data	
		
	 NL	2008	2-50	(B)	 NL	1997	2-50	(C)	 Chi-square	value,	significance	(p-value)	
Incidences	Overall	 13.9/100,000	 16.23/100,000	 Χ2=	.626,	p=.	429	Ages	2-18	 2.15/100,000	 2.32/100,000	 Χ2=	.007,	p=1.00	†	Ages	19-29	 7.52/100,000	 7.70/100,000	 Χ2=	.002,	p=.	969	Ages	30-40	 13.74/100,000	 18.1/100,000	 Χ2=	.486,	p=.	486		Ages	41-50	 32.1/100,000	 43.7/100,000	 Χ2=	1.496,	p=.	221	
Gender	Male	(%)	 80%	 76%	 Χ2=	.216,	p=.	642		
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Gender-wise,	we	see	the	same	trend	here,	a	male-bias	present,	but	again	there	is	a	non-significant	difference	between	the	two	cohorts	(Table	3.2).	
3.2	Cause	of	Death	
	 After	excluding	the	cases	without	autopsy	for	analysis,	in	cohort	A	there	are	9	cases	with	structural	heart	problems,	and	7	without	any	identifiable	cause.		In	the	older	age	cohorts,	B	and	C,	there	are	more	‘structural’	deaths	than	‘no	anatomical	cause’	deaths	(B=	23	‘structural’,	11	‘no	anatomical	cause’,	C=	43	‘structural’,	9	‘no	anatomical	cause’	(Figures	3.3	&	3.4).	This	sharp	increase	in	‘structural’	deaths	is	likely	observed	due	to	the	added	age	group	(41-50’s),	as	both	cohorts	possess	large	structural	numbers	in	these	groups	(2008=	14,	1997=	24).	When	comparing	the	ratio	of	‘structural’	to	‘no	anatomical	cause’	between	cohort	A	and	ON,	there	is	a	non-significant	difference	(p=.	172).	As	well,	comparing	cohort	B	with	cohort	C	gives	a	non-significant	result	(p=.	106).	Overall,	it	is	clear	there	are	more	structural	heart	issues	in	the	older	population,	and	more	unexplainable	deaths	appear	to	be	in	younger	age.		 Upon	further	investigation	of	the	subjects	with	structural	cardiac	issues,	there	were	a	small	number	of	subjects	that	recognized	a	heart	issue	before	death.	In	cohort	A	11.1%	had	a	recognized	issue.	In	cohort	B,	4.3%	had	a	recognized	issue.	In	cohort	C,	30.2%	had	a	recognized	issue.		 	 	
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Figure	3.3:	Causes	of	SCD	by	age	in	NL	2008	cohort	(B).	 	
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Figure	3.4:	Causes	of	SCD	by	age	in	NL	1997	cohort	(C).	 	
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CAD	was	a	major	cause	of	death	in	all	3	cohorts.	In	subjects	in	the	‘structural’	disease	category,	in	cohort	A,	4/9	(44%)	subjects	had	CAD.	In	cohort	B,	16/23	subjects	(70%)	had	CAD,	and	in	cohort	C,	34/43	(79%)	subjects	had	CAD.	Looking	at	the	entire	cohort,	cause	of	death	aside:	cohort	A	had	6/16	(38%)	subjects	with	evidence	of	CAD,	cohort	B	had	19/34	(56%)	of	subjects	with	evidence	of	CAD,	and	cohort	C	had	36/52	(69%)	of	subjects	with	evidence	of	CAD.	The	ON	cohort	for	2008	2-40’s	had	49%	(comparison:	p=	.782)	of	those	with	structural	heart	disease	with	CAD,	and	36%	of	all	SCDs	(comparison:	p=	.918)	with	CAD.	There	does	not	appear	to	be	any	difference	between	NL	and	ON	with	respect	to	CAD.			 While	CAD	played	a	big	role	in	all	three	cohorts,	the	second	most	common	cause	of	death	was	‘no	anatomical	cause’.	The	3rd	most	common	category	was	labeled	‘other’,	which	is	a	miscellaneous	category	(Figures	3.5	&	3.6).	
3.3	Location,	Activity	Level,	&	Symptoms	In	cohort	A,	65%	of	subjects	died	in	their	home.	For	cohort	B,	59%	died	in	their	homes,	and	for	cohort	C	56%	died	at	home.	The	small	number	of	cases	in	each	cohort	that	did	not	die	at	home	succumbed	at	work,	school,	or	public	places.	The	ON	cohort	found	that	72%	of	their	subjects	died	at	home	(Pilmer	et	al.,	2013).	Examining	activity	level	at	time	of	death	shows	that	the	vast	majority	of	cases	in	2008	died	while	at	rest	or	in	sleep	(cohort	A=	71%,	cohort	B	=75%).	Cohort	C	had	only	36%	of	subjects	die	while	at	rest	or	sleep,	however,	there	were			
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Figure	3.5:	Causes	of	SCD	in	the	2008	NL	2-40	cohort	(A).	
	‘Other’	category	includes	valvular	disease,	structural	anomaly,	myocarditis,	suspicious	car	accident,	and	a	drug	overdose.	
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Figure	3.6:	Causes	of	SCD	in	the	2008	and	1997	NL	2-50	cohort	(B	&	C).	
	‘Other’	category	includes	valvular	disease,	structural	anomalies,	myocarditis,	suspicious	accidents,	a	drug	overdose,	a	genetic	condition,	an	AV	node	tumor,	and	a	mitral	valve	prolapse.	
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	16	cases	with		‘unknown’	locations	of	death	in	this	cohort	due	to	lack	of	autopsy	report	detail.	The	second	largest	category	for	activity	level	was	light-moderate	activity.	In	cohort	A,	24%	died	during	light-moderate	exercise.	In	cohort	B,	14%	of	subjects	died	during	light-moderate	exercise,	and	in	cohort	C,	30%	of	subjects	died	during	light-moderate	exercise.	The	last	category	remaining,	and	also	the	smallest	category,	is	moderate-vigorous	activity.		Cohort	A,	B,	and	C	all	had	small	numbers	(5%,	11%,	and	9%,	respectively).	The	ON	cohort	found	a	similar	trend:	11%	of	their	cases	died	during	moderate-vigorous	activity	(Pilmer	et	al.,	2013).	As	well,	ON	found	that	33%	of	their	2-18	age	group	died	during	moderate-vigorous	activity;	however,	in	our	cohorts	all	moderate-vigorous	deaths	were	above	the	age	of	30.	Some	examples	of	moderate-vigorous	activities	in	the	NL	cohorts	are:	playing	racquetball,	manual	labor,	swimming,	and	militia	training	exercise.	In	general,	there	were	very	few	cases	in	all	cohorts	that	experienced	symptoms	before	death.	In	cohort	A,	3	of	17	subjects	had	chest	pains.	Two	of	these	3	subjects	went	to	a	physician	for	investigation,	however	both	were	dismissed	(strained	muscle	in	chest	and	bronchopneumonia).	In	cohort	B,	8	out	of	44	had	chest	pain,	while	one	other	person	had	shortness	of	breath	and	one	other	had	presyncope.	Three	of	the	8	individuals	sought	medical	attention,	but	all	were	dismissed.	In	cohort	C,	7	had	chest	pains,	2	had	shortness	of	breath,	and	8	had	‘other’	symptoms	(ex.	stomach	sick,	dizzy,	heartburn).	Nine	of	these	17	subjects	sought	investigation,	and	6	were	dismissed.	Three	were	awaiting	further	cardiac	investigation.		
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4.	Discussion																			
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							The	question	this	current	study	poses	is	whether	the	scope	and	nature	of	SCD	in	NL	is	of	significance,	and	whether	it	is	a	greater	health	issue	in	NL	than	ON.	We	hypothesized	that	NL	may	have	a	higher	incidence	of	early	SCD	in	this	age	category	due	to	the	known	mutations	causing	heart	diseases	and	unknown	underlying	genetic	causes,	given	the	historical	genetic	isolation	of	the	population.	We	ascertained	cases	of	sudden	death	(SD)	for	the	year	2008	and	1997	(prior	to	the	availability	of	ICDs	in	NL)	and	each	case	was	analyzed	to	determine	likelihood	of	SCD.	The	2008	cohort	(A)	was	compared	to	a	similar	ON	cohort.	We	found	that	there	is	a	statistically	significant	increased	incidence	of	SCD	in	ages	2-40	in	comparison	with	ON	in	2008.	We	also	found	that	the	incidence	of	SCD	increases	with	age,	and	males	are	more	often	the	victims	when	compared	to	the	opposite	gender.	With	regards	to	cause	of	death,	younger	individuals	often	show	no	anatomical	cause	on	autopsy	and	older	individuals	tend	to	show	more	structural	cardiac	issues.	Any	structural	conditions	present	were	most	often	previously	undiagnosed.	The	majority	of	deaths	took	place	while	at	rest	at	home,	and	symptoms	leading	up	to	death	were	uncommon.	
4.1	Incidence		 In	all	cohorts	we	found	a	high	incidence	of	SCD.	Similar	numbers	are	noted	between	2008	and	1997,	for	all	age	groups.	The	study	was	created	with	similar	methodology	to	Pilmer	et	al.	(2013)	for	making	direct	comparisons	with	another	Canadian	province.	They	found	that	for	ages	2-40	in	the	year	2008	the	incidence	was	2.64	per	100,000	persons.		As	already	noted,	our	incidence	surpasses	this	by	almost	3	times.	
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	 Finding	other	comparable	studies	is	a	difficult	task	as	methodology	varies	greatly	throughout	the	literature.	This	variation	often	involves	the	nature	of	the	study	(retrospective	or	prospective),	different	age	groups,	criteria	for	inclusion	or	exclusion	of	the	SD	group,	and	inclusion	or	exclusion	of	non-autopsied	cases.	There	is	one	other	significant	study	in	Canada	(British	Columbia)	that	assessed	incidence	of	SCD	in	those	aged	0-35	from	2005-2007	(Lim	et	al.,	2010).	Lim	et	al.	(2010)	examined	all	deaths	that	were	placed	in	the	‘natural’	and	‘undetermined’	categories,	and	‘accidental’	deaths	were	not	included.	Using	similar	inclusion	and	exclusion	criteria	to	ours,	they	found	the	incidence	of	SCD	was	1.75	per	100,000	persons	per	year	(Appendix	E).	NL	truly	has	a	higher	incidence.	
Other	studies	with	fairly	comparable	methodology	were	completed	in	Ireland,	England,	and	Denmark	(See	comparison	table	in	Appendix	E).	In	Ireland,	a	group	of	researchers	looked	at	SCD	in	ages	15-35	from	2005-2007	(Margey	et	al.,	2011).	The	same	definition	of	sudden	death	was	used	as	our	NL	study.	Unlike	the	current	study,	all	cases	with	any	presence	of	drugs	that	are	known	to	cause	SCD	(ex.	cocaine,	high	alcohol)	were	excluded.	The	incidence	found	was	2.85/	100,000	persons	per	year.	In	England	and	Wales,	researchers	examined	deaths	from	ages	1-34	through	years	2002-2005	(Papadakis	et	al.,	2009).	Their	classification	system	did	include	some	‘accidental’	deaths,	such	as	drowning	incidents,	as	they	recognized	these	might	represent	misclassified	cardiac	deaths.	Overall,	they	found	an	incidence	of	1.8/	100,	000	persons	per	year.	
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	 There	were	two	studies	completed	in	Denmark	spanning	nine	years	(2000-2009)	that	used	the	same	methodology	(Risgaard,	Winkel,	Jabbari,	Behr,	et	al.,	2014;	Winkel	et	al.,	2011).	These	methods	closely	resemble	ours,	and	their	age	group	reached	age	49	which	we	can	compare	to	with	our	age	2-50	cohort.	Another	similarity	is	that	they	included	non-autopsied	cases.	We	do	differ	in	the	use	of	extra	information	outside	the	autopsy	file:	these	studies	used	the	Danish	National	Patient	Registry	for	supplementary	health	information	on	patients.	For	the	age	group	1-35,	the	2011	and	2014	studies	found	similar	results:	2.8	per	100,000	person	years	and	2.3	per	100,000	persons,	respectively.	Interestingly,	NL	differs	in	the	older	age	groups:	Risgaard	et	al.	(2014)	found	that	for	ages	1-49	the	incidence	was	8.6	per	100,000	persons	and	for	ages	36-49	the	incidence	was	21.7/100,000.	NL	has	an	overall	higher	incidence	in	our	2-50	age	groups,	however,	8.6/100,000	is	the	next	highest	value	found	in	the	literature.		The	incidence	for	ages	36-49	is	much	higher	than	our	comparable	values	(13.7/100,000	and	18.1/100,000	for	2008	and	1997,	cohorts	B	&	C,	respectively).	A	possible	explanation	for	this	hike	in	incidence	might	be	due	to	their	greater	percentage	of	non-autopsied	cases	(51%)	compared	to	our	23%	(2008)	and	21%	(1997)	of	non-autopsied	cases.	As	well,	it	was	already	noted	these	studies	had	access	to	a	much	greater	amount	of	health	data	on	the	subjects.	
	 A	consistent	trend,	shown	in	every	one	of	these	studies	reviewed,	is	SCD	increases	in	numbers	with	increasing	age,	and	that	it	is	certainly	more	common	in	males	(Lim	et	al.,	2010;	Margey	et	al.,	2011;	Papadakis	et	al.,	2009;	Pilmer	et	al.,	2013;	Risgaard,	Winkel,	Jabbari,	Behr,	et	al.,	2014).	The	actual	incidences	of	SCD	are	
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not	such	a	consistent	trend;	we	have	a	higher	spectrum	of	numbers.	The	most	likely	explanation	for	the	spike	in	numbers	is	that	NL	is	a	founder	population.	We	directly	compared	with	a	comparably	more	outbred	population	(ON)	and	found	NL	to	have	a	significantly	higher	SCD	incidence.	It	has	been	established	that	there	are	lethal	SCD	genes	present	in	NL	(Merner	et	al.,	2008),	and	this	may	account	for	the	higher	incidence.	Certainly	we	know	that	TMEM43	plays	a	role	in	SCD	in	NL;	however,	we	also	know	that	there	are	multiple	mutations	present	in	NL	as	our	clinic	has	649	families	referred	total,	and	the	category/condition	with	the	largest	number	of	families	is	SCD	(K.	Hodgkinson,	personal	communication,	September	25th,	2014).		
To	confirm	our	suspicions	of	genetic	etiology	of	young	SCD	in	NL	we	hope	to	perform	DNA	testing	of	the	victims	in	our	present	cohort	with	a	panel	of	genetic	mutations,	TMEM43	included.	When	genetic	testing	is	completed	at	time	of	autopsy,	it	is	referred	to	as	a	molecular	autopsy.	It	is	a	crucial	step	for	identifying	cause	of	young	SCD,	especially	when	there	are	no	structural	findings	on	autopsy.	This	has	been	done	before	in	various	studies	and	has	shown	diagnostic	yield	of	the	molecular	autopsy	to	be	up	to	35%	(D.	J.	Tester	&	Ackerman,	2007;	D.	J.	Tester,	Spoon,	Valdivia,	Makielski,	&	Ackerman,	2004).	Other	studies	report	different	numbers	(Dean	et	al.,	2015;	D.	J.	Tester,	Medeiros-Domingo,	Will,	Haglund,	&	Ackerman,	2012),	within	a	0-35%	range,	that	may	be	a	reflection	of	a	variety	of	clinical	and	methodological	issues	relating	to	selection	bias	of	population	studied,	genetic	mutations	included	on	the	panel	etc.	(Semsarian,	Ingles,	&	Wilde,	2015).		
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		 The	pertinent	question	is:	what	else	could	cause	this	increase?	Lifestyle	factors	come	to	mind,	and	more	specifically	obesity.	Obesity	is	linked	with	SCD	(Tavora	et	al.,	2012),	and	NL	is	one	of	the	‘heaviest’	provinces	in	Canada	(Canada,	2011;	Twells	et	al.,	2014).	The	comorbidities	associated	with	obesity	are	proven	risk	factors	for	heart	disease	(Luo	et	al.,	2007;	Van	Gaal,	Mertens,	&	De	Block,	2006;	Zalesin,	Franklin,	Miller,	Peterson,	&	McCullough,	2011).	Conversely,	it	is	possible	for	obese	persons	to	be	living	without	any	comorbidity	at	all,	which	begs	the	question:	is	obesity	alone	a	causative	factor	for	SCD?	To	further	understand	how	obesity	is	contributing	to	SCD,	we	need	to	see	the	health	records	of	the	SCD	subjects.	In	saying	so,	lifestyle	factors	will	be	looked	at	more	in-depth	in	upcoming	studies.		
4.2	Causes	of	Death	From	autopsy	review,	information	on	cause	of	death	can	be	deducted.	We	found	in	cohort	A	that	9/16	(56%)	had	structural	abnormalities	noted	on	autopsy,	while	44%	could	not	be	given	a	cause	of	death,	as	no	anatomic	abnormalities	were	present.		This	ratio	between	‘structural’	and	‘no	anatomical	cause’	was	similar	to	what	Pilmer	et	al.	(2013)	found	(non-significant	difference).	As	previously	discussed,	we	have	found	that	NL	has	a	higher	incidence	of	SCD	than	ON.	The	results	show	that	NL	has	proportionally	more	deaths	in	arrhythmic	deaths	and	structural	deaths;	neither	category	alone	accounts	for	the	difference	between	NL	and	ON.	With	the	notion	that	arrhythmias	are	often	due	to	a	genetic	cause	and	that	the	majority	of	structural	deaths	come	from	CAD,	this	could	possibly	mean	that	NL	has	more	genetic	related	cardiac	deaths.	
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Similar	proportions	of	numbers	can	be	noted	in	other	studies	as	well.	In	a	comparable	retrospective	study	in	Australia,	autopsies	were	reviewed	between	1994-2002	in	those	aged	35	and	less	(Doolan	et	al.,	2004).	This	review	showed	that	31%	of	SCDs	had	no	established	cause	of	death.	In	the	Irish	review	conducted	by	Margey	et	al.	(2011)	on	14-35	year	olds,	they	found	that	26.7%	of	SCD	victims	had	SADS	(sudden	arrhythmic	death	syndrome)	–	a	synonym	for	no	anatomical	cause	found	on	autopsy.	In	both	of	these	studies,	the	category	of	‘no	anatomical	cause’	was	considered	the	highest	in	their	cohorts.		
Contrary	to	this,	the	English	study	on	those	ages	1-34	years	found	ischemic	heart	disease	to	be	the	highest	category	(33.5%)	with	SADS	in	third	at	14%	(Papadakis	et	al.,	2009).	In	the	Veneto	region	of	Italy	a	study	was	completed	whereby	they	analyzed	273	SCDs	in	the	time	frame	of	1979-1998	(Corrado	et	al.,	2001).	The	cases	were	analyzed	in	a	similar	manner	as	previously	mentioned	studies,	however	there	was	further	microscopic	and	histologic	analysis	than	in	comparable	studies.	They	initially	found	that	28%	of	their	cases	appeared	to	have	no	anatomical	cause	of	death-	a	number	similar	to	other	reports.	However,	with	further	analysis,	79%	of	those	cases	were	found	to	have	actual	physiological	issues	discovered	with	a	more	thorough	autopsy,	leaving	only	6%	of	the	273	victims	to	have	died	with	no	anatomical	cause	of	death.	This	is	an	interesting	and	unique	finding,	and	speaks	to	the	idea	that	we	may	need	more	rigorous	and	thorough	autopsies	on	possible	SCDs.	
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CAD	was	widespread	in	our	study,	being	the	top	cause	of	death	in	the	2008	and	1997	age’s	2-50	cohorts	(B	&	C),	and	3rd	in	2008	2-40	cohort	(A).		ON	showed	a	similar	amount	of	CAD	in	their	cohort	(non-significant	difference).	In	the	Danish	study	by	Risgaard	et	al.,	they,	similar	to	us,	examined	an	older	cohort,	1-49	years	old	(2014).		Their	most	common	cause	of	death	was	CAD	(158/439;	36%).	Another	study	with	an	older	age	sample	was	completed	in	the	United	States	by	Eckart	et	al.	(2011).	They	found	that	for	subjects	≥35	years	the	leading	cause	of	death	was	CAD,	with	an	incidence	of	13.69	per	100,000	person-years	for	those	≥35	years.	Both	of	these	studies	report	the	same	trend	that	our	study	also	corroborates:	in	those	≤35	years	old,	SUD	is	significantly	more	common	than	CAD	(p<.001),	and	in	those	≥35	years	old,	CAD	is	significantly	more	common	than	SUD	(p<.001)	(Eckart	et	al.,	2011;	Risgaard,	Winkel,	Jabbari,	Behr,	et	al.,	2014).	
It	is	clear	from	our	study	and	previous	literature	that	there	is	a	portion	of	deaths	that	appear	to	be	due	to	an	arrhythmia,	as	no	cause	of	death	is	found	on	autopsy.	These	deaths	tended	to	occur	in	the	younger	ages.	Genetic	testing	at	time	of	autopsy	would	help	clarify	the	cause	of	these	deaths	by	possibly	diagnosing	a	channelopathy.	As	for	structural	diseases,	CAD	is	the	most	prevalent	and	most	commonly	reported	in	the	literature,	and	tends	to	effect	the	older	populations.	
4.3	Circumstances	of	Death			 The	current	study	shows	that	the	majority	of	victims	of	SCD	died	during	rest	or	during	sleep,	with	the	smallest	proportion	dying	during	moderate	to	vigorous	
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activity.	In	the	SCD	field	of	research,	athletic	activity	has	long	been	under	suspicion	for	causing	SCD	(Maron,	Roberts,	McAllister,	Rosing,	&	Epstein,	1980).	There	is	an	abundance	of	evidence	to	support	this	theory	(Harmon,	Drezner,	Wilson,	&	Sharma,	2014);	however,	it	appears	that	SCD	is	more	prevalent	in	the	general	population,	and	here	athletic	activity	is	not	the	causative	agent	(Risgaard,	Winkel,	Jabbari,	Glinge,	et	al.,	2014).		The	ON	study	found	a	similar	result,	with	11%	of	SCDs	occurring	during	moderate-vigorous	activity	(Pilmer	et	al.,	2013).	This	is	further	corroborated	by	the	Irish	group	that	found	7.7%	(9/116)	of	subjects.	SCDs	occurred	during	athletic	activity	while	the	majority	died	during	rest	or	sleep	(Margey	et	al.,	2011).	Finally,	the	same	result	was	seen	in	Denmark	where	only	11%	(43/409)	of	subjects	died	during	vigorous	activity	while	84%	(347/409)	of	subjects	died	during	rest	or	sleep	(Winkel	et	al.,	2010).	
	 Ascertaining	whether	the	victim	was	symptomatic	or	not	before	death	can	be	a	challenging	task,	as	it	is	not	always	properly	documented	and	we	did	not	have	access	to	medical	records.	We	found	that	only	a	small	percentage	of	victims	in	all	cohorts	displayed	any	premonitory	symptoms.	The	literature	tends	to	agree	with	this	finding.	Eckart	et	al.	(2011)	documented	symptoms	in	278	(53%)	of	those	who	died,	such	as	chest	pain,	dyspnea,	and	syncope.		While	this	is	indeed	a	higher	number	than	we	found,	they	agreed	that	it	is	difficult	to	obtain	any	prodrome	as	it	most	often	occurs	immediately	antecedent	to	death.	Contrary	to	these	findings,	a	recent	study	examined	CAD	victims	(age	1-35	years)	by	comparing	their	symptoms	with	sex	and	age	matched	controls	that	died	in	accidents	(Jabbari	et	al.,	2013).	They	found	that	
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62%	of	young	persons	with	SCD	experienced	angina	before	death.		There	is	a	wide	spectrum	of	causative	diseases	and	syndromes	that	cause	SCD,	therefore	it	is	logical	that	there	may	be	a	wide	spectrum	of	symptoms	as	well.	
4.4	Limitations	
	 Notably,	a	few	limitations	are	present	regarding	discrepancies	between	our	study	and	the	ON	study.	Most	importantly,	we	endeavored	to	design	our	study	based	directly	on	the	ON	published	manuscript	(Pilmer	et	al.,	2013),	which	was	lacking	in	explicit	methodology	in	some	areas.	For	example,	the	manner	in	which	they	made	exclusions	was	unclear,	and	led	to	us	using	a	slightly	different	process.	That	being	said,	the	data	used	for	primary	analysis	(the	‘sudden	death’	group)	was	collected	exactly	as	ON	indicated,	therefore	overall	this	is	a	minor	limitation.	It’s	also	challenging	to	directly	compare	ourselves	to	ON	when	we	have	knowingly	used	a	completely	different	panel	of	individuals	to	assess	the	likeliness	of	SCD.	However,	for	NL	to	reach	a	non-significant	difference	compared	to	ON,	we	would	have	had	to	incorrectly	assess	6	deaths,	as	non-significance	(p>.05)	is	reached	at	11	sudden	deaths	(we	had	17).	Proportionally,	this	is	a	large	number	to	have	erred	and	is	thus	unlikely.		More	limitations	stem	from	the	retrospective	nature	of	this	study.	Data	collection	was	limited	to	what	was	in	the	files	–	which	at	times	was	missing	information	-	as	the	primary	purpose	of	these	files	is	to	satisfy	pathology	requirements,	not	SCD	requirements.	To	stay	true	to	the	design	and	the	ON	study,	we	did	not	attempt	to	look	for	additional	information	elsewhere.	For	example,	not	
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every	file	included	toxicology	info,	which	may	contribute	to	SCD.	However,	the	vast	majority	had	toxicology	in	the	file	when	the	circumstances	of	death	suggested	it.		Another	important	limitation	that	became	apparent	with	file	review	was	the	different	standard	of	autopsy	reporting	between	pathologists.	While	the	Chief	Medical	Examiner	reviews	all	autopsies,	there	are	certainly	differences	between	files	depending	on	the	pathologist	who	performed	the	autopsy.	Firstly,	not	all	subjects	had	autopsies,	which	is	typically	at	the	discretion	of	the	pathologist,	and	sometimes	the	families.	This	often	occurred	in	motor	vehicle	accidents,	where	cause	of	death	was	presumed	to	be	the	accident.	In	our	analysis,	however,	the	main	‘sudden	death’	group	(2-40)	had	only	1	subject	without	autopsy,	thus	it	likely	did	not	impact	our	final	result.	Also	dependent	on	the	pathologist	is	the	list	of	major	findings	for	an	autopsy,	noted	on	the	first	page.	We	found	that	some	lists	would	be	missing	a	SCD	major	finding,	of	for	example	an	enlarged	heart,	while	others	might	have	included	it	-	it	was	not	consistent.	This	could	easily	influence	a	reader	of	an	autopsy	to	miss	the	finding	of	an	enlarged	heart,	as	the	‘major	findings’	are	summarized	on	the	first	page.	An	example	of	this	was	a	case	of	a	27	year	old	male	involved	in	a	skidoo	accident,	with	cause	of	death	presumed	asphyxia/drowning,	and	incidentally	had	a	650g	heart	and	fat	in	the	right	ventricle.	The	cardiomegaly	here	was	not	researched	any	further	and	was	listed	with	no	further	investigations.	For	our	study,	we	paid	attention	to	the	entirety	of	the	autopsy	and	this	type	of	incidental	finding	was	not	likely	to	be	have	been	missed.			
	 61	
Finally,	something	that	is	missing	from	most	autopsies	is	the	molecular	pathology.	This	would	indicate	whether	the	subject	had	any	significant	genetic	mutations	that	could	have	caused	their	death.	Very	few	of	the	reviewed	files	included	this,	as	it	is	not	yet	part	of	the	standard	autopsy.	We	are	hoping	to	review	DNA	from	fixed	blocks	in	a	future	study.		 On	a	final	note,	the	sample	size	in	this	study	is	small,	however,	it	is	as	large	as	it	can	be	given	our	population	numbers.		With	this,	it	is	possible	we	are	missing	some	significant	relationships	in	the	data	because	our	numbers	are	too	small	to	show	significance.	We	are	currently	working	to	collect	more	data	from	different	years	to	hopefully	better	this	issue.	
4.5	Strengths	
	 A	significant	strength	of	this	study	is	that	we	are	essentially	a	single-center	study	that	captures	all	cases	in	NL.	We	do	indeed	have	a	centralized	database,	but	more	than	that	is	that	all	cases	in	NL	are	sent	directly	to	the	Chief	Medical	Examiner	(S.A.)	to	be	reviewed,	which	limits	any	bias	in	ascertainment	because	we	used	a	single	assessor.	Additionally,	it	increases	the	likelihood	that	we	captured	all	SCD	cases	in	NL	in	2008	and	1997.	Another	important	advantage	of	the	study	is	that	it	was	designed	as	closely	as	possible	to	replicate	a	non-founder	population	(ON)	study,	allowing	us	to	make	a	direct	comparison	between	founder	and	non-founder	populations.	 			
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4.6	Future	Research	and	Conclusion		 This	study	is	the	very	first	piece	of	the	puzzle;	it	provides	the	basic	information	we	need	to	start	understanding	the	burden	SCD	causes	in	NL.	We	know	already	there	are	genetic	mutations	in	the	NL	population,	and	now	we	have	a	potential	measure	of	this	effect.	To	confirm	that	the	deaths	we	measured	are	an	outcome	of	genetics,	a	next	step	would	be	to	investigate	molecular	studies;	all	SCD	subjects	in	2008	have	fixed	tissue	blocks,	we	will	be	testing	these	for	mutations.	It	would	also	be	important	to	examine	lifestyle	and	environmental	factors	in	future	studies	that	might	be	responsible	for	the	effect	we	have	seen.	Finally,	we	will	assess	more	years	to	confirm	the	numbers	we	have	described,	to	make	sure	the	incidence	rates	are	consistent	over	time.	It	is	reassuring,	however,	that	we	found	a	very	similar	incidence	for	the	year	1997,	which	would	indicate	the	numbers	from	2008	are	not	outliers.		 To	conclude,	NL	has	a	significantly	higher	incidence	of	SCD	in	the	2008	2-40	year	old	cohort	than	the	comparable	ON	cohort.	These	deaths	comprise	both	structural	and	arrhythmogenic	diseases,	with	the	trend	of	more	arrhythmogenic	issues	in	the	young	and	more	structural	disease	with	age.	The	incidence	of	SCD	increases	with	age,	and	is	more	prevalent	in	males.	The	burden	that	the	NL	population	endures	is	still	not	fully	understood,	however,	this	study	has	brought	to	light	that	SCD	is	a	significant	source	of	young	death	in	the	province,	and	will	inform	health	policy	in	a	way	that	will	hopefully	work	to	prevent	many	future	sudden	deaths.		
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Appendix	A	–	Current	Known	Gene	Mutations	Discovered	with	a	Potential	for	SCD	("ClinVar,"	2014;	"Gene,"	2014;	"MalaCards	Human	Disease	Database,"	2014)	
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Cardiac	Disease	 	 Gene	 Locus	 Official	full	name	
Hypertrophic	
Cardiomyopathy	 ACTC1	 15q14		 actin,	alpha,	cardiac	muscle	1		 CALR3	 19p13.11		 calreticulin	3		 CAV3	 3p25	 caveolin	3		 CMH21	 7p12.1-q21		 cardiomyopathy,	familial	hypertrophic,	21			 COA5	 2q11.1	 cytochrome	c	oxidase	assembly	factor	4		 CSRP3	 11p15.1		 cysteine	and	glycine-rich	protein	3		 JPH2	 20q13.12		 junctophilin	2		 MT-ATP6	 --	 mitochondrially	encoded	ATP	synthase	6			 MT-TG	 --	 mitochondrially	encoded	tRNA	glycine			 MT-TH	 --	 mitochondrially	encoded	tRNA	histidine		 MT-TI	 --	 mitochondrially	encoded	tRNA	isoleucine			 MYBPC2	 19q13.33		 myosin	binding	protein	C		 MYBPC3	 11p11.2	 cardiac	myosin-binding	protein	C,	fast	type		 MYH6	 14q12		 myosin,	heavy	chain	6,cardiac	muscle,	alpha		 MYH7			 14q11.2-q12	 β-myosin	heavy	chain		 MYL2	 12q24.11	 myosin,	light	chain	2,	regulatory,	cardiac,	slow		 MYLK2	 20q13.31		 myosin	light	chain	kinase	2	
Hypertrophic	
Cardiomyopathy		
Cont’d	 MYL3	 p21.3-p21.2		 myosin	light	chain	3,alkali;	ventricular,	skeletal,	slow	MYO6	 6q13	 myosin	VI			 MYOZ2	 4q26-q27		 myozenin	2	
	 72	
	 NDUFV2	 18p11.22	 NADH	dehydrogenase	flavoprotein	2,	24kDa		 NEXN	 1p21.1	 nexilin	(F	actin	binding	protein)		 PLN	 6q22.1	 phospholamban		 PRKAG2	 7q36.1	 protein	kinase,	AMP-activated,	gamma	2	non-catalytic	subunit			 SLC25A4	 4q35	 solute	carrier	family	25	(mitochondrial	carrier;	adenine	nucleotide	translocator),	member	4			 TCAP	 17q12		 titin-cap		 TNNC1	 3p21.1	 troponin	C	type	1	(slow)		 TNNI3	 19q13.4	 troponin	I	type	3	(cardiac)		 TNNT2	 1q32	 cardiac	troponin	T	type	2		 TPM1	 15q22.1		 tropomyosin	1	(alpha)		 TTN	 2q31	 titin		 VCL	 10q22.2		 vinculin	
Arrhythmogenic	
Right	Ventricular	
Cardiomyopathy/	
Dysplasia	
CTNNA3	 10q22.2	 catenin	(cadherin-associated	protein),	alpha	3			 DSC2	 18q12.1			 desmocollin	2		 DSG2	 18q12.1-q12.2	 desmoglein	2		 DSP	 6p24	 desmoplakin		 JUP	 17q21	 junction	plakoglobin		 PKP2	 12p11	 plakophilin	2		 RYR2	 1q43	 ryanodine	receptor	2	(cardiac)	
Arrhythmogenic	
Right	Ventricular	
Cardiomyopathy/	
Dysplasia	Cont’d	
TGFB3	 14q24	 transforming	growth	factor,	beta	3	
	 TMEM43	 3p25.1	 transmembrane	protein	43	
	 73	
Dilated	
Cardiomyopathy	 ABCC9	 12p12.1	 ATP-binding	cassette,	sub-family	C	(CFTR/MRP	,	member	9		 ACTC1	 15q14		 actin,	alpha,	cardiac	muscle	1		 ACTN2	 1q42-q43	 actinin,	alpha	2		 BAG3	 10q25.2-q26.2	 BCL2-associated	athanogene	3		 CMD1B	 9q13-q22	 cardiomyopathy,	dilated	1B	(autosomal	dominant)			 CMD1H	 2q14-q22	 cardiomyopathy,	dilated	1H	(autosomal	dominant)		 CMD1K	 6q12-q16		 cardiomyopathy,	dilated	1K	(autosomal	dominant)		 CMD1Q	 7q22.3-q31.1		 cardiomyopathy,	dilated	1Q	(autosomal	dominant)		 CRYAB	 11q22.3-q23.1	 crystallin,	alpha	B		 CSRP3	 11p15.1		 cysteine	and	glycine-rich	protein	3		 DES	 2q35	 desmin			 DMD	 Xp21.2	 dystrophin		 DNAJC19	 3q26.33	 DnaJ	(Hsp40)homolog,	subfamily	C,	member	19		 DOLK	 9q34.11		 dolichol	kinase		 DSG2	 18q12.1-q12.2	 desmoglein	2		 DSP	 6p24	 desmoplakin		 EYA4	 6q23	 EYA	transcriptional	coactivator	and	phosphatase	4			 FHL2	 2q12.2	 four	and	a	half	LIM	domains	2		 FKTN	 9q31-q33	 fukutin	
Dilated	
Cardiomyopathy	
Cont’d	 FOXD4	 9p24.3	 forkhead	box	D4		 GATAD1	 7q21-q22		 GATA	zinc	finger	domain	containing	1	
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	 GJA5	 1q21.1	 gap	junction	protein,	alpha	5,	40kDa		 KCNH2	 7q36.1	 potassium	voltage-gated	channel,	subfamily	H	(eag-related),	member	2			 LAMA3	 18q11.2			 laminin,	alpha	3		 LAMA4	 6q21	 laminin,	alpha	4		 LDB3	 10q22.3-q23.2	 LIM	domain	binding	3		 LMNA	 1q22	 lamin	A/C		 MT-TH	 --	 mitochondrially	encoded	tRNA	histidine		 MT-TY	 --	 mitochondrially	encoded	tRNA	tyrosine			 MURC	 9q31.1	 muscle-related	coiled-coil	protein		 MYBPC3	 11p11.2	 myosin	binding	protein	C,	cardiac		 MYH6	 14q12		 myosin,	heavy	chain	6,cardiac	muscle,	alpha		 MYH7	 14q12	 myosin	heavy	chain	7,	cardiac	muscle,	beta		 MYPN	 10q21.3	 myopalladin		 NEXN	 1p21.1	 nexilin	(F	actin	binding	protein)		 PDCD1	 2q37.3	 programmed	cell	death	1		 PLN	 6q22.1	 phospholamban		 PRDM16	 1p36.23-p33	 PR	domain	containing	16		 PSEN1	 14q24.3	 presenilin	1		 PSEN2	 1q42.13	 presenilin	2		 RAF1	 3p25	 Raf-1	proto-oncogene,	serine/threonine	kinase		
Dilated	
Cardiomyopathy	
Cont’d	 RBM20	 10q25.2	 RNA	binding	motif	protein	20		 RYR2	 1q43	 ryanodine	receptor	2	(cardiac)	
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	 SCN5A	 3p21	 sodium	channel,	voltage-gated,	type	V,	alpha	subunit			 SDHA	 5p15	 succinate	dehydrogenase	complex,	subunit	A,	flavoprotein		 SGCD	 5q33-q34	 sarcoglycan,	delta	(35kDa	dystrophin-associated	glycoprotein)			 TAZ	 Xq28	 tafazzin		 TCAP	 17q12		 titin-cap		 TMPO	 12q22	 thymopoietin		 TNNC1	 3p21.1	 troponin	C	type	1	(slow)		 TNNI1	 1q12	 troponin	I	type	1	(skeletal,	slow)			 TNNI3	 19q13.4	 troponin	I	type	3	(cardiac)		 TNNT2	 	 troponin	T	type	2	(cardiac)		 TPM1	 15q22.1	 tropomyosin	1	(alpha)		 TTN	 2q31	 titin		 TXNRD2	 22q11.21	 thioredoxin	reductase	2		 VCL	 10q22.2	 vinculin		 ZASP	 7	 ZO-2	associated	speckle	protein	
Long	QT	
Syndrome	 AKAP9	 7q21-q22	 	A	kinase	(PRKA)	anchor	protein	9		 ALG10	 12p11.1	 ALG10,	alpha-1,2-glucosyltransferase		 ANK2	 4q25-q27	 ankyrin	2,	neuronal		 ANKB	 4q25-q27	 ankyrin	B		 CACNA1C	 2p13.3	 l-type	calcium	channel		 CALM2	 2p21	 calmodulin	2	(phosphorylase	kinase,	delta)			 CAV3	 3p25	 caveolin	3		 KCNE1	 21q22.12		 potassium	voltage-gated	channel,	Isk-related	family,	member	1		
Long	QT	
Syndrome	Cont’d	 KCNE2	 21q22.12		 potassium	voltage-gated	channel,	Isk-related	family,	
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member	2		 KCNH2	 7q36.1	 potassium	voltage-gated	channel,	subfamily	H	(eag-related),	member	2			 KCNJ2	 17q24.3	 K	inwardly-rectifying	channel,	subfamily	J,	member	2		 KCNJ5	 11q24	 potassium	inwardly-rectifying	channel,	subfamily	J,	member	5				 KCNQ1	 11p15.5	 potassium	voltage-gated	channel,	KQT-like	subfamily,	member	1			 NOS1AP	 1q23.3	 nitric	oxide	synthase	1	(neuronal)	adaptor	protein		 SCN4B	 11q23.3	 sodium	channel,	voltage-gated,	type	IV,	beta	subuni			 SCN5A	 3p21-p24	 sodium	channel,	voltage-gated,	type	V,	alpha	subunit			 SNTA1	 20q11.2	 syntrophin,	alpha	1	
Catecholaminergic	
Polymorphic	
Ventricular	
Tachycardia		
ANK2	 4q25-q27	 ankyrin	2,	neuronal	
	 ASPH	 8q12.1	 aspartate	beta-hydroxylase		 CALM1	 14q32.11	 calmodulin	1	(phosphorylase	kinase,	delta)			 CALR	 19p13.3-p13.2		 calreticulin		 CAMP	 3p21.3	 cathelicidin	antimicrobial	peptide	
Catecholaminergic	
Polymorphic	
Ventricular	
Tachycardia	
Cont’d	
CASQ2	 1p13.3	 calsequestrin	2	
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	 FKBP1B	 2p23.3	 FK506	binding	protein	1B,	12.6	kDa		 KCNJ2	 17q24.3	 K	inwardly-rectifying	channel,	subfamily	J,	member	2		 RYR1	 19q13.1	 ryanodine	receptor	1	(skeletal)		 RYR2	 1q43	 ryanodine	receptor	2	(cardiac)		 TRDN	 6q22.21	 triadin	
Brugada	
syndrome	 CACNA1C	 2p13.3	 calcium	channel,	voltage-dependent,	L	type,	alpha	1C	subunit			 CACNB2	 10p12	 calcium	channel,	voltage-dependent,	beta	2	subunit			 GPD1L	 3p22.3	 glycerol-3-phosphate	dehydrogenase	1-like		 HCN4	 15q24.1	 hyperpolarization	activated	cyclic	nucleotide-gated	potassium	channel	4			 KCNE3	 11q13.4	 potassium	voltage-gated	channel,	Isk-related	family,	member	3			 SCN1B	 19q13.1	 sodium	channel,	voltage-gated,	type	I,	beta	subunit			 SCN3B	 11q23.3	 sodium	channel,	voltage-gated,	type	III,	beta	subunit			 SCN5A	 3p21-p24	 sodium	channel,	voltage-gated,	type	V,	alpha	subunit	
Short	QT		
Syndrome	 CACNA2D1	 7q21-q22	 calcium	channel,	voltage-dependent,	alpha	2/delta	subunit	1		
Short	QT		
Syndrome	Cont’d	 KCNH2	 7q36.1	 potassium	voltage-gated	channel,	subfamily	H	(eag-related),	member	2			 KCNJ2	 17q24.3	 K	inwardly-rectifying	
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channel,	subfamily	J,	member	2		 KCNQ1	 11p15.5	 potassium	voltage-gated	channel,	KQT-like	subfamily,	member	1			 	
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Appendix	B	–	Sample	Medical	Examiner’s	report	
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Appendix	C-	Chart	Audit	Form	
Data	Collection	Autopsy	#	Study	Number	Postal	Code	Year	of	Birth	Date	of	death	Sex	Height	(cm)	Weight	(kg)	BMI	Manner	of	Death	
Medical	Cause	of	Death	
Underlying	pathology	(pick	1	or	more)	Previously	known	cardiac	disease	
If	yes,	indicate	underlying	pathology	(pick	1	or	more)	
If	yes,	indicate	additional	information	of	interest	(testing	performed,	previous	health	records)		Cardiac	risk	factors	
Other	potentially	contributory	medical	conditions	
Medications	before	death	
Non-prescription	or	recreational	drugs	(not	including	vitamins)	
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Circumstances/location	of	death	Activity	level	at	onset	of	fatal	event	Specify	if	known	
Symptoms	in	preceding	24	hours	
If	symptoms,	circumstances	(same	definitions	as	above)	Symptoms	prior	to	preceding	24	hours	
If	symptoms,	circumstances	(same	definitions	as	above)	Were	symptoms	preceding	death	investigated?		
List/summarize	medical	investigations/test	results:		
Reported	family	history	of	sudden	death	or	arrhythmia	If	yes,	circumstances	of	death	
If	positive	family	history	of	sudden	death,	closest	affected	individual	Genetic	Testing?	
Additional	comments	from	the	narrative		
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Appendix	D	-	Primary	data	used	for	analysis.		
NL	and	ON	population	data:	Stats	Canada	(Statistics	Canada,	2014b)	and	Pilmer	el,	2013,	respectively.	
	 NL	2008	2-40	(A)		&	2-50	(B)	 NL	1997	2-50	(C)	 Ontario	2008	2-40		 Deaths	(n=)	 Population	size	 Deaths	(n=)	 Population		size	 Deaths	(n=)	 Population	size	Overall	 	17	(A)		44	(B)	 232,210	(A)	316,244	(B)	 66	 406,713	 174	 6,602,680	Ages	2-18	 2	 92,982	 3	 129,125	 19	 2,652,751	Ages	19-29	 5	 66,452	 7	 90,909	 47	 1,945,419	Ages	30-40	 10	 72,776	 18	 99,593	 105	 1,980,743	Ages	41-50	 27	 84,034	 38	 87,043	 	 	Male		(n/total	deaths)	 11/17	(A)	35/44	(B)	 50/66	 132/174	
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Appendix	E	–	Comparison	of	incidences	across	the	literature	
Author	 Population	 Year	 Age	
Group	
Incidence	
(person-
years)	
Key	
Differences	Current	study	 NL,	Canada	 2008	 2-40	years	 7.32/100,000		 N/A	Current	study	 NL,	Canada	 2008	 2-50	years	 13.9/100,000		 N/A	Current	study	 NL,	Canada	 1997	 2-50	years	 16.23/100,000		 N/A	Pilmer	et	al.,	2013	 ON,	Canada	 2008	 2-40	years		 2.64/100,000	 None	Lim	et	al.,	2010	 British	Columbia,	Canada	 2005-2007	 0-35	years	 1.75/100,000	 No	accidentals	included	Margey	et	al.,	2011	 Ireland	 2005-2007	 15-35	years	 2.85/100,000	 Cases	with	drug	involvement	excluded	Papadakis	et	al.,	2009	 England	and	Wales	 2002-2005	 1-34	years	 1.8/100,000	 No	access	to	autopsy	files,	only	used	office	of	national	statistics	database	Winkel	et	al.,	2011	 Denmark	 2000-2006	 1-35	years	 2.8/100,000	 Used	info	outside	of	autopsy	file	Risgaard	et	al.,	2014	 Denmark	 2007-2009	 1-49	years	 8.6/100,000	 Used	info	outside	of	autopsy	file	and	used	high	number	of	non-autopsy	cases	
36-49	years	 21.7/100,000	
	
